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Abstract
Background: Mice lacking surfactant protein-A (SP-A-/-; knockout; KO) exhibit increased vulnerability to infection
and injury. Although many bronchoalveolar lavage (BAL) protein differences between KO and wild-type (WT) are
rapidly reversed in KO after infection, their clinical course is still compromised. We studied the impact of SP-A on
the alveolar macrophage (AM) proteome under basal conditions. Male SP-A KO mice were SP-A-treated (5
micrograms/mouse) and sacrificed in 6 or 18 hr. The AM proteomes of KO, SP-A-treated KO, and WT mice were
studied by 2D-DIGE coupled with MALDI-ToF/ToF and AM actin distribution was examined by phalloidon staining.
Results: We observed: a) significant differences from KO in WT or exogenous SP-A-treated in 45 of 76 identified
proteins (both increases and decreases). These included actin-related/cytoskeletal proteins (involved in motility,
phagocytosis, endocytosis), proteins of intracellular signaling, cell differentiation/regulation, regulation of
inflammation, protease/chaperone function, and proteins related to Nrf2-mediated oxidative stress response
pathway; b) SP-A-induced changes causing the AM proteome of the KO to resemble that of WT; and c) that SP-A
treatment altered cell size and F-actin distribution.
Conclusions: These differences are likely to enhance AM function. The observations show for the first time that
acute in vivo SP-A treatment of KO mice, under basal or unstimulated conditions, affects the expression of multiple
AM proteins, alters F-actin distribution, and can restore much of the WT phenotype. We postulate that the SP-A-
mediated expression profile of the AM places it in a state of “readiness” to successfully conduct its innate immune
functions and ensure lung health.
Introduction
SP-A, a multi-functional protein, is known to play an
important role in host defense. SP-A is a collectin, or
collagenous lectin, that can recognize pathogen-asso-
ciated molecular patterns (PAMP). The recognition and
binding of PAMP is complex and may involve binding
sites in addition to the C-type carbohydrate recognition
domain. Although the direct interaction with pathogens
constitutes one aspect of its host defense function, SP-A
also plays a role in the clearance of particulate matter,
allergens, and debris from the alveolar surface [1-5]. SP-
A appears to have a regulatory role on the alveolar
macrophage by influencing the expression of a number
of cytokines, including TNF-a,I L - 1 b, and others [6-16],
and cell surface molecules, such as CD11b (CR3), TLR2
and TLR4, the mannose receptor, scavenger receptor A,
and CD14 [17-21]. Moreover, SP-A can help regulate
redox balance [22-26], enhance bacterial phagocytosis by
alveolar macrophages [27-30], contribute to bacterial
killing [31-33], affect the development of dendritic cells
[34], and provide an interface between innate and adap-
tive immunity [35]. Despite this diverse array of func-
tions, many gaps remain in our knowledge of how SP-A
influences lung host defense and the cell types it affects,
especially under basal or unstimulated conditions.
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ability to infection and injury. This has been illustrated
with mouse models of pneumonia with organisms
including Klebsiella pneumoniae, Streptococcus pneumo-
niae, Pseudomonas aeruginosa, Pneumocystis carinii,
respiratory syncytial virus, and others [28,36-41].
Although the increased susceptibility was initially
thought to be a consequence of the absence of the sti-
mulatory effect of SP-A on phagocytosis, recent studies
suggest a more complex picture. We have recently
shown that in the absence of SP-A, baseline levels of
many host defense molecules in bronchoalveolar lavage
(BAL) samples [26,42] differ significantly (including both
increases and decreases) from those in WT mice. How-
ever, although many of these differences in the SP-A
KO mice are rapidly compensated for during infection
and reach levels comparable to those of WT mice, the
clinical course, and survival in particular [28] of the KO
mice remains less favorable compared to that of the
WT mice [27]. This may indicate that along with known
direct effects of SP-A on phagocytosis and bacterial kill-
ing, there may be other direct and indirect effects of SP-
A that may be instrumental in determining the clinical
course and that these effects cannot occur in the
absence of SP-A.
A likely source of these host defense deficits in the
SP-A KO mouse is the alveolar macrophage, the pri-
mary effector cell for innate immunity in the lung.
Although macrophages, which are derived from blood
monocytes, are found throughout the body, their pheno-
type may vary depending on their environment. Alveolar
macrophages exhibit a unique phenotype [43] that is
clearly influenced by the presence of SP-A [17-21,27,28],
but the extent of this influence is not entirely known.
Moreover, virtually nothing is known about the in vivo
effect of SP-A on the alveolar macrophage proteome
under basal or unstimulated conditions, with regards to
whether and which groups of proteins SP-A may affect
under such conditions. However, based on recent in
vitro studies, in response to LPS [44] or in extrapulmon-
ary tissues [45], it appears that the integrity of the cytos-
keleton is required in order for SP-A-mediated
processes to occur.
In this study we tested the hypothesis that SP-A exerts
a significant impact on the pattern of protein expression
by the alveolar macrophage under basal or unstimulated
conditions to make the alveolar macrophage ready and
competent to subsequently mount a successful innate
host defense response in response to various injurious
agents. Towards this end we employed two-dimensional
difference gel electrophoresis (2D-DIGE) to study in
vivo the changes in the macrophage proteome in
response to SP-A treatment of SP-A KO mice, the func-
tional groups the changed proteins belong to, and
whether the SP-A-induced changes render the proteome
from alveolar macrophages of the KO mice more like
that of wild type (WT) mice. SP-A KO mice treated
with SP-A and sacrificed at different times post-treat-
ment, as well as WT mice on the same C57BL/6 genetic
background were used in this study. The data were sub-
jected to various analytical methods to assess, in an
unbiased fashion, the similarities and differences in the
proteomes of our experimental groups, as well as, by
considering the function of the changed proteins, to
obtain insight into underlying mechanisms and the SP-
A-mediated functions of the alveolar macrophage. Based
on the findings a “p r o o fo fp r i n c i p l e ” experiment was




The cells from all BAL samples were subjected to total
and differential cell countst oe x c l u d ea n ym i c ew i t h
underlying infectious or inflammatory processes. No evi-
dence of inflammation or infection was seen in any of
the mice. The total cell counts did not differ signifi-
cantly from one another and all BAL samples consisted
of > 95% macrophages (data not shown).
Protein content was the same in all samples (data not
shown) and identical amounts of protein (20 μg) were
loaded on all gels.
2-D DIGE results
Overview
Following automatic spot detection and manual editing,
791 protein spots were defined and matched across 2D-
DIGE gels from all samples and then subjected to
further analysis. A reference gel is shown in Figure 1.
Details of 2D-DIGE processing and data analysis are
provided in Additional Files 1 and 2. When experimen-
tal groups were compared, ANOVA (p < 0.05) revealed
significant differences in 234 spots, and these were sub-
jected to additional analyses (Figures 2, 3, 4 and 5). The
initial analysis was done using the individual spots data.
All 791 spots were harvested from a preparative gel and
we were able to identify 76 distinct proteins by MALDI-
ToF/ToF with confidence intervals > 95% and ProteinPi-
lot scores of > 61. The identified proteins were made up
of 191 spots including “nearest neighbor” IDs and
accounted for 24.1% of the detectable protein spots and
70.2% of the stained protein on 2D-DIGE gels. On the
reference gel in Figure 1 the identified proteins with 191
spots circled are shown. The identified proteins were
entered into the Ingenuity Pathways Analysis program
to gain further insight into biological processes that
might be affected (Table 1). Some of these identified
proteins consisted of multiple spots and statistical
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of all of the spots constituting a specific protein in each
of our functional groups (Tables 2, 3, 4, 5, and 6). As
mentioned above, some of the individual proteins are
represented by a single spot and others may be one of
multiple spots making up isoforms of a specific protein.
Pairwise statistical comparisons between treatment
groups were then done for both the individual spots and
identified proteins and the results are summarized in
Figure 5. Assignment of all identified proteins into sub-
groups is provided in Additional File 3 and comparisons
for all identified proteins are listed in Additional File 4.
Principal Component Analysis
When principal component analysis (PCA) was per-
formed on the significantly different spots, the markers
for the four gels (each marker represents the gel from
o n ei n d i v i d u a la n i m a lw i t h i na ne x p e r i m e n t a lg r o u p )
were grouped fairly tightly, and each of the experimental
groups was well separated from one another (Figure 2).
The first principal component accounted for 39.27% of
t h ev a r i a n c ea n dt h es e c o n da c c o u n t e df o r2 3 . 0 2 % .I n
each group (KO mice, WT mice, and KO mice treated
with SP-A for 18 hr), the four individual points are all
rather tightly grouped indicating relatively small var-
iance within each group. The KO mice treated with SP-
A for 6 hr are not grouped as tightly indicating greater
Figure 1 Reference gel image of mouse alveolar macrophage
proteins identified by 2D-DIGE. Some of the proteins may include
multiple spots reflecting different isoforms, fragments, or multimers
(see also Additional File 3). 1, 65-kDa macrophage protein; 2, Actin
related protein 2/3 complex, subunit 5; 3, Actin-related protein 3; 4,
Actr2 protein; 5, Alpha-fetoprotein; 6, Annexin A2; 7, Annexin A4; 8,
Anxa5 protein; 9, ArsA arsenite transporter, ATP-binding, homolog 1;
10, Atp5b protein; 11, Calpain, small subunit 1; 12, Capping protein
(actin filament) muscle Z-line, alpha 2; 13, Capping protein (actin
filament) muscle Z-line, beta isoform a; 14, Cathepsin D precursor; 15,
Chaperonin subunit 2 (beta); 16, Chia protein; 17, Chitinase 3-like 3
precursor; 18, Chitinase-related protein MCRP; 19, Chloride intracellular
channel 1; 20, Chloride intracellular channel 4; 21, CNDP dipeptidase 2;
22, Coactosin-like 1; 23, EF hand domain containing 2; 24, Eno1 protein
(Alpha-enolase); 25, Eukaryotic translation initiation factor 5A; 26, Ezrin;
27, F-actin capping protein alpha-1 subunit; 28, Ferritin heavy chain 1;
29, Ferritin light chain 1; 30, Gamma-actin; 31, Gelsolin precursor; 32,
Glucose-6-phosphate dehydrogenase X-linked; 33, Guanine deaminase;
34, Heat shock protein 1, beta; 35, Heat shock protein 5 precursor; 36,
Heat shock protein 65; 37, Heat shock protein 8; 38, Heat shock protein
90, beta (Grp94), member 1; 39, Hematopoietic cell specific Lyn
substrate 1; 40, Heme-binding protein; 41, Heterogeneous nuclear
ribonucleoprotein K; 42, High mobility group 1 protein; 43, Hnrpf
protein; 44, Kappa-B motif-binding phosphoprotein; 45, Keratin
complex 2, basic, gene 8; 46, Keratin type II; 47, Krt13 protein; 48,
Laminin receptor; 49, Major vault protein (MVP); 50, Microtubule-
associated protein, RP/EB family, member 1; 51, Myosin light chain,
regulatory B-like; 52, Nucleophosmin 1; 53, p50b; 54, Peroxiredoxin 2;
55, Prolyl 4-hydroxylase, beta polypeptide precursor; 56, Proteasome
(prosome, macropain) 28 subunit, alpha; 57, Proteasome alpha 1
subunit; 58, Protein disulfide isomerase associated 6; 59, Protein
disulfide-isomerase A3 precursor; 60, Protein synthesis initiation factor
4A; 61, Purine nucleoside phosphorylase; 62, Put. beta-actin (aa 27-375);
63, Rab GDP dissociation inhibitor beta; 64, Rho GDP dissociation
inhibitor (GDI) alpha; 65, Rho, GDP dissociation inhibitor (GDI) beta; 66,
Serine (or cysteine) proteinase inhibitor, clade B, member 1a; 67,
Stathmin; 68, Superoxide dismutase 1, soluble; 69, Superoxide
dismutase 1, soluble; 70, Tropomyosin 3, gamma; 71, Tubulin, beta 5;
72, Tyrosine 3/tryptophan 5-monooxygenase activation protein,
epsilon polypeptide; 73, Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta polypeptide; 74, Vacuolar
adenosine triphosphatase subunit B; 75, Valosin-containing protein; 76,
Vimentin.
Figure 2 Principal component analysis. A plot of the principal
component analysis for the 234 significant (ANOVA, p < 0.05)
protein spots is shown. The markers represent the weighted
average for the first two principal components for the 234 proteins
for each individual in each of the groups: SP-A knockout (KO) (●),
SP-A knockout treated with SP-A for 6 hr (KO 6 hr SP-A) (▲), SP-A
knockout treated with SP-A for 18 hr (KO 18 hr SP-A) (♦), and wild
type (WT) (■).
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responding to SP-A treatment. The relative positions of
each group are also informative. A clear separation
between WT and KO mice is evident based on principal
component 1. However, the KO mice treated with SP-A
for 6 hr are quite different from the KO baseline mice
and the WT baseline mice. By contrast, at 18 hr after
SP-A treatment the mice, based on principal component
1, are in closer proximity to the WT baseline mice than
the KO baseline group indicating their overall greater
Figure 4 Gel comparisons. Locations of spots with significant
changes by direct comparisons (t-test, p < 0.05) are mapped to
show significant increases in red and significant decreases in green.
Comparisons include: Panel A, SP-A KO to KO 6 hr SP-A; Panel B,
KO to KO 18 hr SP-A; Panel C, KO to WT; and Panel D,W Tt oK O
18 hr SP-A. The text box with each image lists the total significant
changes, significant increases, and significant decreases as both the
number of protein spots (#) and percent of total volume (%vol) of
resolved protein on the gel.
Figure 5 Summary of significant changes. In Panel A the graphs
depict the number of significant changes in protein spots (from a
total of 791) compared to KO (left) or WT (right). The black bar
represents the total significant changes, the white bars represent
significant decreases, and the gray bars represent significant
increases. In Panel B the same changes are shown but in this case
the changes evaluated were in the 76 identified proteins.
Figure 3 Heat map and dendrogram of protein spots with
significant changes (ANOVA, p < 0.05). Panel A. A heat map
depicts differences in protein expression from the SP-A knockout
(KO). A line representing each numbered protein spot that was found
to be significantly different by ANOVA is colored using a red to green
scale with dark red indicating the greatest increases and dark green
indicating the greatest decreases. Baseline KO is represented by the
yellow column on the left. Each of the 234 significant protein spots is
indicated by a colored bar. Proteins at levels higher than in the KO
mice are in red (dark red > 25% increase; orange < 25% increase).
Protein spots with levels lower than in the KO mice are indicated in
green (dark green > 25% decrease; light green < 25% decrease). Map
columns include: column 1, spot number (#); column 2, SP-A
knockout (KO) (columns 3-5 are compared to this value); column 3,
differences between KO vs. KO treated with SP-A for 6 hr (KO 6 hr SP-
A); column 4, differences between KO vs. SP-A knockout treated with
SP-A for 18 hr (KO 18 hr SP-A); and column 5, differences between
KO vs. wild type (WT). Panel B. A dendrogram has been generated
showing hierarchical clustering of protein spots based on expression
profiles derived from the data depicted in the heat map. Each leaf or
line on the left of the dendrogram corresponds to the adjacent bar
in the heat map. On the dendrogram protein spots with similarities
in their expression patterns are grouped together. The labeled
groups indicate groups or protein spots that tended to be at their
highest level in the indicated group (i.e the group labeled WT protein
spots were at higher levels in WT than the other groups), although
there were some exceptions (see results). Smaller distances between
branches indicate a more similar expression profile. The clustering of
the expression profiles of protein spots for this experiment can easily
be seen by the division of the significant (ANOVA, p < 0.05) protein
spots that are typically at their highest levels in the designated
group.
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treatment.
Heat diagram
A dynamic picture of the changes in expression is
afforded by the heat diagram in Figure 3A. The relative
expression levels depicted by the heat diagram provide
the basis for defining the expression patterns that are
summarized by the dendrogram (Figure 3B). In this dia-
gram the KO baseline mice (1st column in yellow) pro-
vide the reference values to which the other groups are
compared. Each of the 234 significant protein spots is
indicated by a colored bar. Proteins at levels higher than
in the KO mice are in red (dark red > 25% increase;
orange < 25% increase). Protein spots with levels lower
than in the KO mice are indicated in green (dark green
> 25% decrease; light green < 25% decrease). It is readily
apparent that both increases and decreases occur in all
of the experimental groups compared to KO mice and,
based on the preponderance of the green color in the
diagram, most of the proteins are at higher levels in the
KO baseline mice. However, a variety of expression pat-
terns can be distinguished. For example, near the top of
the diagram there are more than a dozen orange bars in
the 6 hr group, indicating an increase over KO baseline
levels. In the 18 hr and WT columns most of these have
become green, indicating that the increases were transi-
ent and that most of the proteins have fallen to levels
below those seen in KO baseline mice. In the bottom
h a l fo ft h ed i a g r a m ,t h e r ea r ean u m b e ro fo r a n g ea n d
dark red bars at 6 hr that remain red in the 18 hr SP-A
group and in the WT group, indicating a persistent
increase in the levels of these proteins after SP-A treat-
ment of KO mice that resembles the WT levels. A num-
ber of other patterns are present representing increases
and decreases and/or transient and sustained changes.
The heat map shows a shift of changes with time after
SP-A treatment towards the WT phenotype.
Cluster analysis
In Figure 3B the arrangement of the clusters produced
by hierarchical clustering of the data depicted in the
heat diagram (Figure 3A) is portrayed with a dendro-
gram in which the 234 significant spots are grouped
according to patterns of protein expression as levels of
each spot are compared in the various experimental
groups. With this arrangement the changes between
groups can clearly be seen along the axis of the dendro-
gram, where protein spots are bracketed together and
labeled with the group name where they are typically
being expressed at the highest levels. For example, in
the WT portion of the dendrogram, each leaf or each
line (which represents one protein spot) on the axis is a
protein that is typically (but not always) found at higher
levels in the WT group compared to any of the other
groups. The expression of more than half of the signifi-
cant spots was highest in the untreated KO mice. The 6
hr SP-A, 18 hr SP-A, and WT groups all have approxi-
mately equal numbers of spots reaching their highest
levels in each group. There were two major branches in
the dendrogram. One represents the untreated KO mice
and the other represents the two SP-A-treated KO
groups and the WT mice. Within that second branch,
the two SP-A-treated KO groups had a common sub-
branch and were separated from the WT mice. The
overall dendrogram analysis indicates that the KO and
WT mice are on different branches and clearly sepa-
rated from one another, whereas the treated mice share
a common branch with the WT and appear to be closer
to them than the KO mice. Although, as stated above,
spots are typically at their highest abundance in the
named category (KO 6 hr SP-A, WT, etc.), there are
exceptions. An example of this is seen in the heat map
at the top of the KO 6 hr SP-A column where there are
a number of spots that are at their most abundant level,
as indicated by the orange and red bars. It is also impor-
tant to note that the KO division of the dendrogram has
two major branches. At the top of the dendrogram, the
smaller first branch appears to represent many protein
spots that are at higher levels in the 6 hr SP-A-treated
group, but then apparently (at 18 hr, green bars in heat
map) drop to levels below those of the KO mice, sug-
gesting a transient response at 6 hr (as discussed above).
These spots could potentially be viewed as more related
to the major 6 hr SP-A cluster. The much larger
remainder of the KO branch contains multiple subdivi-
sions, but all represent protein spots that are typically at
lower levels in the SP-A-treated groups and the WT
than in the KO mice.
Gel maps of protein changes
Figure 4 shows the reference gel with significant differ-
ences in protein spots between groups colored either
green for decreases or red for increases. The significant
differences are noted as the number of spots (out of a
total of 791 spots) that changed significantly, and as the
percentage of total volume of protein on the gel that are
represented by the significant spots. Total volume is
determined by adding the densitometric values of all of
Table 1 p values for pathways identified by Ingenuity
Pathways Analysis.
IPA Top Canonical Pathways p-value
Regulation of Actin-based Motility by Rho 6.85E-08
RhoA Signaling 3.98E-07
Actin Cytoskeleton Signaling 3.35E-06
Fcg Receptor-mediated Phagocytosis in Macrophages and
Monocytes
3.36E-06
Clathrin-mediated Endocytosis Signaling 6.11E-05
NRF2-mediated Oxidative Stress Response 1.09E-4
Phelps et al. Proteome Science 2011, 9:67
http://www.proteomesci.com/content/9/1/67
Page 5 of 21the expressed proteins resolved on the gel. Panels A
through C of Figure 4 show changes as compared to the
KO baseline control animals. In Panel D the protein
spots from WT mice are compared to those of the KO
mice 18 hr after SP-A treatment.
Comparison of the KO baseline mice to the KO 6 hr
animals (Panel A) revealed 113 significant changes (41
increases and 72 decreases) accounting for 14.3% (5.2%
increases and 9.1% increases) of the resolved protein.
The largest number of significant changes is seen when
KO baseline mice are compared to KO 18 hr. There are
233 significant changes with approximately 2/3 being
proteins that are at higher levels in the KO mice (Panel
B). The 233 protein spots make up 29.5% of the resolved
protein on the gel. Of these, 78 are proteins expressed at
increased levels and 155 are proteins expressed at
Table 2 Changes in actin-related/cytoskeletal (ARC) proteins (as compared to KO baseline).
Gel No. Protein Name KO 6 hr SP-A KO 18 hr SP-A WT
1 65-kDa macrophage protein ↓↓ * ↓
2 Actin related protein 2/3 complex, subunit 5 ↓ UN ↑
3 Actin-related protein 3 ↓* ↓* ↓
4 Actr2 protein ↓↓ ↓
6 Annexin A2 ↓* ↓* ↓*
11 Calpain, small subunit 1 ↓↓ * ↓
12 Capping protein (actin filament) muscle Z-line, alpha 2 (CapZ alpha-2) ↓↑ ↑
13 Capping protein (actin filament) muscle Z-line, beta isoform a (CapZ beta) ↓* ↓↓
15 Chaperonin subunit 2 (beta) ↓↓ * ↓*
19 Chloride intracellular channel 1 ↓↓ * ↓*
20 Chloride intracellular channel 4 (mitochondrial) ↑↑ * ↑
22 Coactosin-like 1 ↑↑ * ↑
24 Eno1 protein (Alpha-enolase) ↑↓ ↓
25 Eukaryotic translation initiation factor 5A ↑↑ ↑
26 Ezrin ↓↓ * ↓*
27 F-actin capping protein alpha-1 subunit (CapZ alpha-1) ↑↑ ↑
30 Gamma-actin ↓↓ * ↓*
31 Gelsolin precursor ↑↓ ↑
33 Guanine deaminase ↓↓ ↓
34 Heat shock protein 1, beta ↑↓ ↑
39 Hematopoietic cell specific Lyn substrate 1 UN ↑↑
45 Keratin complex 2, basic, gene 8 ↓↑ ↑ *
46 Keratin type II ↓↓ * ↓
47 Krt13 protein ↑↑ * ↓
49 Major vault protein (MVP) ↓* ↓* ↓*
50 Microtubule-associated protein, RP/EB family, member 1 ↓↓ * ↓
51 Myosin light chain, regulatory B-like ↑↑ ↑
53 p50b; Leukocyte-specific protein 1 (LSP1) ↓↓ ↓
62 Put. beta-actin (aa 27-375) ↑↑ * ↑
63 Rab GDP dissociation inhibitor beta ↓↓ * ↓*
64 Rho GDP dissociation inhibitor (GDI) alpha ↑↓ ↓
65 Rho, GDP dissociation inhibitor (GDI) beta ↑↑ ↑
67 Stathmin ↑↑ ↑ *
69 Tropomodulin 3 ↑↑ ↑
70 Tropomyosin 3, gamma ↓↓ ↑
71 Tubulin, beta 5 ↑↓ ↑
75 Valosin-containing protein ↓↓ * ↓*
76 Vimentin ↑↓ ↓ *
Total changes 21↓,1 6 ↑, 1UN 24↓,1 3 ↑, 1UN 21↓,1 7 ↑
Total significant changes 4↓*1 3 ↓*, 4↑*9 ↓*, 2↑*
Comparison of mean normalized volumes (see Additional File 4) for proteins from KO mice to KO 6 hr SP-A, KO 18 hr SP-A, and wild-type mice. Increased (↑),
decreased (↓), unchanged (UN), determined to be significant (p < 0.05) by t-test (*).
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Gel No. Protein Name KO 6 hr SP-A KO 18 hr SP-A WT
5 Alpha-fetoprotein ↑* ↑* ↑
6 Annexin A2 ↓* ↓* ↓*
7 Alpha-fetoprotein ↓↓ ↓
16 Chia protein ↓↑ ↓
17 Chitinase 3-like 3 precursor (Ym1) ↑↓ * ↓*
18 Chitinase-related protein MCRP ↑↑ ↓
24 Eno1 protein (Alpha-enolase) ↑↓ ↓
25 Eukaryotic translation initiation factor 5A ↑↑ ↑
34 Heat shock protein 1, beta (HSP90AB1) ↑↓ ↓
35 Heat shock protein 5 precursor (GRP78) ↑↓ * ↓
36 Heat shock protein 65 (HSP60) ↓↓ * ↓*
37 Heat shock protein 8 (HSC70, HSC71) ↑↑ ↓
38 Heat shock protein 90, beta (Grp94), member 1 ↓↓ * ↓*
39 Hematopoietic cell specific Lyn substrate 1 UN ↑↑
40 Heme-binding protein ↓↓ ↓ *
42 High mobility group 1 protein ↑↓ ↑
53 p50b; Leukocyte-specific protein 1 (LSP1) ↓↓ ↓
72 Tyrosine 3/tryptophan 5-monooxygenase activation protein, ε ↑↓ ↓
73 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, b ↑↓ ↓
76 Vimentin ↑↓ ↓ *
Total changes 7↓,1 2 ↑, 1UN 14↓,6 ↑ 16↓,4 ↑
Total significant changes 1↓*, 1↑*5 ↓*, 1↑*6 ↓*
Comparison of mean normalized volumes (see Additional File 4) for proteins from KO mice to KO 6 hr SP-A, KO 18 hr SP-A, and wild-type mice. Increased (↑),
decreased (↓), unchanged (UN), determined to be significant (p < 0.05) by t-test (*).
Table 4 Changes in protease balance/chaperone function (PBCF) proteins (as compared to KO baseline).
Gel No. Protein Name KO 6 hr SP-A KO 18 hr SP-A WT
11 Calpain, small subunit 1 ↓↓ * ↓
14 Cathepsin D precursor ↓↓ ↓
15 Chaperonin subunit 2 (beta) ↓↓ * ↓*
19 Chloride intracellular channel 1 ↓↓ * ↓*
21 CNDP dipeptidase 2 ↓* ↓* ↓
22 Coactosin-like 1 ↑↑ * ↑
24 Eno1 protein (Alpha-enolase) ↑↓ ↓
34 Heat shock protein 1, beta (HSP90AB1) ↑↓ ↓
35 Heat shock protein 5 precursor (GRP78) ↑↓ * ↓
36 Heat shock protein 65 (HSP60) ↓↓ * ↓*
37 Heat shock protein 8 (HSC70, HSC71) ↑↑ ↓
38 Heat shock protein 90, beta (Grp94), member 1 ↓↓ * ↓*
55 Prolyl 4-hydroxylase, beta polypeptide precursor ↑* ↑↓ *
56 Proteasome (prosome, macropain) 28 subunit, alpha ↓↑ ↑
57 Proteasome alpha 1 subunit ↓↓ ↓
58 Protein disulfide isomerase associated 6 ↓↓ ↓
59 Protein disulfide-isomerase A3 precursor ↓↓ ↓
66 Serine (or cysteine) proteinase inhibitor, clade B, member 1a ↓↑ ↑
75 Valosin-containing protein ↓↓ * ↓*
Total changes 13↓,6 ↑ 14↓,5 ↑ 16↓,3 ↑
Total significant changes 2↓*8 ↓*, 1↑*6 ↓*
Comparison of mean normalized volumes (see Additional File 4) for proteins from KO mice to KO 6 hr SP-A, KO 18 hr SP-A, and wild-type mice. Increased (↑),
decreased (↓), unchanged (UN), determined to be significant (p < 0.05) by t-test (*).
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KO baseline mice. These proteins make up 9.9% and
19.6% of the resolved protein, respectively. When the
KO to KO 18 hr gel and the KO to WT gel are com-
pared, the pattern of changes is similar, suggesting that
many of the changes in protein expression resulting
from the exogenous SP-A treatment are restoring pro-
tein levels to those approximating the levels characteriz-
ing the WT phenotype. This trend can be further seen
when the WT is compared to the KO 18 hr (Panel D).
The number of significant changes is markedly reduced,
confirming the similarity of these two groups. In this
comparison there are only 88 protein spots that differ
significantly, making up 10.8% of total resolved protein.
Panels A and D each depict a lower number of changes
compared to Panels B and C, indicating that the protein
expression profiles, in terms of the magnitude and num-
ber of changing spots, are closer to KO (after 6 hr of
SP-A treatment) and WT (after 18 hr of SP-A treat-
ment) profiles, respectively. This can be better
Table 5 Changes in regulatory/differentiative processes (RDP) proteins (as compared to KO baseline).
Gel No. Protein Name KO 6 hr SP-A KO 18 hr SP-A WT
25 Eukaryotic translation initiation factor 5A ↑↑ ↑
41 Heterogeneous nuclear ribonucleoprotein K ↓* ↓* ↓*
42 High mobility group 1 protein ↑↓ ↑
43 Hnrpf protein ↓↓ ↓
44 Kappa-B motif-binding phosphoprotein ↓↓ ↓
52 Nucleophosmin 1 ↓↓ ↓
53 p50b ↓↓ ↓
60 Protein synthesis initiation factor 4A ↑↓ ↓ *
Total changes 5↓,3 ↑ 7↓,1 ↑ 6↓,2 ↑
Total significant changes 1↓*1 ↓*2 ↓*
Comparison of mean normalized volumes (see Additional File 4) for proteins from KO mice to KO 6hr SP-A, KO 18hr SP-A, and wild-type mice. Increased (↑),
decreased (↓), unchanged (UN), determined to be significant (p < 0.05) by t-test (*).
Table 6 Changes in Nrf2-regulated (NRF) proteins (as compared to KO baseline).
Gel No. Protein Name KO 6 hr SP-A KO 18 hr SP-A WT
1 65-kDa macrophage protein ↓↓ * ↓
14 Cathepsin D precursor ↓↓ ↓
20 Chloride intracellular channel 4 (mitochondrial) ↑↑ * ↑
28 Ferritin heavy chain 1 ↓↑ * ↓
29 Ferritin light chain 1 ↓* ↓↓
30 Gamma-actin ↓↓ * ↓*
31 Gelsolin precursor ↑↓ ↑
32 Glucose-6-phosphate dehydrogenase X-linked ↓↓ * ↓*
34 Heat shock protein 1, beta (HSP90AB1) ↑↓ ↓
35 Heat shock protein 5 precursor (GRP78) ↑↓ * ↓
38 Heat shock protein 90, beta (Grp94), member 1 ↓↓ * ↓*
45 Keratin complex 2, basic, gene 8 ↓↑ ↑ *
47 Krt13 protein ↑↑ * ↓
54 Peroxiredoxin 2 ↓ UN ↑
57 Proteasome alpha 1 subunit ↓↓ ↓
60 Protein synthesis initiation factor 4A ↑↓ ↓ *
62 Put. beta-actin (aa 27-375) ↑↑ * ↑
68 Superoxide dismutase 1, soluble ↑↑ ↓
71 Tubulin, beta 5 ↑↓ ↑
75 Valosin-containing protein ↓↓ * ↓*
76 Vimentin ↑↓ ↓ *
Total changes 11↓,1 0 ↑ 14↓,6 ↑, 1UN 15↓,6 ↑
Total significant changes 1↓*5 ↓*, 4↑*6 ↓*, 1↑*
Comparison of mean normalized volumes (see Additional File 4) for proteins from KO mice to KO 6 hr SP-A, KO 18 hr SP-A, and wild-type mice. Increased (↑),
decreased (↓), unchanged (UN), determined to be significant (p < 0.05) by t-test (*).
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ber of spots changes as well as the numbers of spots
increased and decreased in each experimental group
compared to KO or WT are graphed. A similar conclu-
sion is reached in Panel B of Figure 5 where the same
comparisons are made using the 76 identified proteins
rather than the 791 total protein spots.
In Additional File 4 the mean normalized volumes
(+/- SD) are given for all 76 identified proteins and sig-
nificant differences for comparisons for each experimen-
tal group between groups that are statistically significant
are indicated.
Categorization of identified proteins
We used different approaches as done previously
[26,42,46] with other types of samples (BAL proteins,
plasma proteins) to assess the function of the set of 76
identified proteins and their biological relevance to
macrophage function. Valuable insight was provided by
analyzing the data with the Ingenuity Pathways Analysis
(IPA) program. These analyses identified: 1) regulation
of actin-based motility; 2) Rho A signaling; 3) Actin
cytoskeletal signaling; 4) Fcg receptor-mediated phago-
cytosis; 5) clathrin-mediated endocytosis signaling; and
6) the NRF2-mediated oxidative stress response (Table
1). However, as often occurs with IPA, PANTHER, and
similar programs, available information is limited
because many published functions/relationships of speci-
fic proteins have not yet been included and an organ/
tissue-specific context is frequently lacking. Another fre-
quent challenge is that functions are sometimes subdi-
v i d e di n t os om a n ys u b g r o u p st h a tt h eo v e r a l l
significance is diminished. For these reasons, we also
employed a manual curation approach, emphasizing
findings from the literature related to the lung and
macrophages, where available. This approach, as did
IPA, strongly implicated motility, phagocytosis, actin sig-
naling, and endocytosis (which we retained as a single
functional group of “actin-related/cytoskeletal proteins”
rather than dividing it into 4 subgroups) as the most
involved cellular processes and included 37 of the 76
proteins identified in our study (Table 2). Given the role
of the alveolar macrophage as a mobile phagocyte, this
was anticipated and the identification of a substantial
subset of identified proteins involved in these processes
indicates that SP-A plays a pivotal role in these macro-
phage functions.
Other major processes implicated by our protein list
included regulation of inflammation (19 proteins) (Table
3), protease balance/chaperone function (18 proteins)
(Table 4), regulatory/differentiative processes (8 pro-
teins) (Table 5), and Nrf2-regulated proteins (21 pro-
teins) (Table 6). All proteins and the functional groups
they were assigned to are listed in Additional File 3
[47-115]. These functional groups also represent
important facets of alveolar macrophage biology and
t h e r e b yc o n s t i t u t eav a l u a b l et o o li na s s e s s i n gm a c r o -
phage function in the presence or absence of SP-A. Pro-
tease/chaperone function may be very important in the
repair of damage to lung tissue and proteins potentially
resulting from exposure to noxious material or patho-
gens and other danger signals. Similarly, the regulation
of inflammatory processes is extremely important for
innate immune processes, with dysregulation of inflam-
mation playing a central role in many pulmonary disease
processes. Finally, the profound differences between cir-
culating blood monocytes and the alveolar macrophage
[43,116,117] and between macrophages that have under-
gone different modes of activation [116,118] indicate the
presence of an active regulatory mechanism directing
the differentiation of macrophages from monocytes and
their activation in various directions.
In addition to the functional categories described
above, 21 of the identified proteins (~15-20) have been
reported to be regulated by Nrf2. All of these have been
reported to either contain antioxidant response elements
(ARE) in their genes, or have been demonstrated to be
Nrf2-regulated. We did not include proteins that may
interact with Nrf2, but are not regulated by it. Nrf2, and
its inhibitor, Keap1, are instrumental in regulating pro-
teins that contain an ARE in their promoter regions and
have been shown to regulate many antioxidant proteins,
a number of cytoprotective enzymes (including Phase 2
detoxifying enzymes), as well as a number of heat shock
proteins/chaperones. These proteins help maintain
redox balance in the lung by limiting the effects of exo-
genous and endogenous reactive oxidant species. A
number of the identified proteins fall into these cate-
gories. In some cases (ferritin light and heavy chain, glu-
cose-6-phosphate dehydrogenase, peroxiredoxin,
superoxide dismutase, valosin-containing protein, et al.)
the presence of an ARE in their genes has been docu-
mented, confirming this potential regulatory mechanism.
However, many other proteins that we identified have
functions such as those listed above that are typically
viewed as Nrf2-regulated. Of significant relevance, Nrf2/
Keap1 activity can be regulated by interaction with actin
filaments [119], adding another dimension to the biolo-
gical relevance of the changes occurring in the many
actin-related/cytoskeletal proteins we identified in the
present study.
Cell area and F-actin measurements after SP-A treatment
Given the relatively large number of actin-related/cytos-
keleton proteins that changed in response to SP-A, as
“proof of principle” we measured cell size and levels of
F-actin. In macrophages that were treated with SP-A for
6 hr and stained with Alexa Fluor 488 phalloidon we
examined cell area (Figure 6A) and the mean
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the amount of F-actin/cell. Data were acquired from >
100 cells obtained from 5 mice. Analysis of cell size
revealed that control macrophages from SP-A KO mice
were significantly (p = 0.0016) smaller than macro-
phages from the same mice that were treated in vitro
with SP-A for 6 hr. The mean fluorescence intensity/
pixel in cells after SP-A treatment for 6 hr was signifi-
cantly (p = 0.016) reduced to approximately 1/2 of that
seen in the control cells.
Macrophages treated with SP-A for 1 hr and their
controls (Figure 6C, D), the cell size and the mean
fluorescence intensity/pixel exhibited similar changes to
those seen at 6 hr. In fact, at the 1 hr time point (a time
point used in several studies in which we studied phago-
cytosis as a biological readout [27,29]) cell size increased
three-fold after SP-A treatment and the mean fluores-
cence intensity/pixel decreased almost four-fold. Both
differences were highly significant (p < 0.0001; p <
0.0001).
Discussion
The absence of SP-A in KO mice has been shown to
increase susceptibility to infection, compromise bacterial
clearance and survival from pneumonia, and adversely
affect the response to various other types of lung injury
[26,28,33,36-42,120]. However, virtually nothing is
known about the impact of SP-A on the alveolar macro-
phage proteome under basal or unstimulated conditions.
We employed a discovery proteomics approach to inves-
tigate, in vivo, the impact of SP-A on global protein
expression by the alveolar macrophage as a way of gain-
ing insight into molecules and mechanisms affected by
SP-A under basal conditions. We thus studied and com-
pared the intracellular proteome of the alveolar macro-
phage from WT mice and SP-A KO mice, and SP-A KO
mice “rescued” with exogenous SP-A and sacrificed at 6
hr, a time point we have previously shown to be suffi-
c i e n tf o rt h es a m ed o s eo fe x o g e n o u sS P - At or e s t o r e
tubular myelin formation in KO mice [121], and 18 hr
after treatment. In the present study under basal condi-
tions we observed: 1) differences in individual protein
content between macrophages from KO and WT mice;
2) that a single in vivo treatment of KO mice with SP-A
exerted a significant impact on the expression of pro-
teins by alveolar macrophages compared to untreated
KO mice; 3) as the time after SP-A treatment of KO
mice increased, the proteomic profile more closely
approximated that of WT mice; 4) a diverse set of SP-
A-dependent functions in the alveolar macrophage,
some of which have not been identified in vivo pre-
viously; including proteins involved in the regulation of
the cytoskeleton; and 5) changes in F-actin and cell size
of the alveolar macrophage in response to SP-A.
In previous studies of BAL proteome analysis, SP-A
was found, under both resting conditions and after var-
ious perturbations (infection, ozone exposure), to have a
major impact on BAL protein expression, particularly
with respect to proteins involved in host defense or the
regulation of redox balance [26,42]. Proteins secreted by
the alveolar macrophage, and by other lung cells (parti-
cularly epithelial cells), together with proteins from
plasma, are the principal sources of BAL protein. The
observations made here indicate that the alveolar
macrophage may also be a significant contributor to the
observed BAL changes. Furthermore, the observed
alveolar macrophage proteome changes in response to
SP-A may contribute to the SP-A-dependent differences
in the phagocytic function of these cells, which may in
turn contribute to differences in disease susceptibility.
In fact, it has been shown that both the phagocytic
activity of the alveolar macrophages from SP-A KO
Figure 6 Determinations of macrophage cell area and F-actin
measurements after SP-A treatment. SP-A KO alveolar
macrophages were isolated, cultured overnight, and treated with
SP-A (or its control). The cells were then fixed, permeabilized,
stained with Alexa Fluor 488 phalloidin, and analyzed as described.
A) Cell area is indicated for control and SP-A-treated macrophages
after 6 hr of SP-A treatment. The data shown represent
measurements of cell area made on cells (n = 115 cells for control;
n = 102 cells for SP-A-treated) from 5 mice. T-test indicates a
significant difference (*) between groups (p = 0.0016). B) F-actin
levels are represented by mean fluorescence intensity/pixel. The
data were obtained from analysis of the same number of mice and
cells indicated in Panel A. The two groups were significantly
different (*; p = 0.016). C) Cell area was determined from
macrophages after one hour of SP-A treatment. Control values (n =
60 cells) and SP-A treated values (n = 62 cells) were significantly
different (*; p < 0.0001). D) F-actin levels in the samples described in
Panel C, as represented by mean fluorescence intensity/pixel, were
significantly different (*; p < 0.0001).
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promised compared to WT mice following infection
with K. pneumoniae i nt h ep r e s e n c eo ra b s e n c eo f
ozone-induced oxidative stress [27,28]. The present find-
ings, as assessed by the multitude of molecules and
pathways affected by SP-A, support the notion that the
alveolar macrophage from the KO mice is not biologi-
cally “ready” to successfully combat injurious agents,
and hence the poorer clinical outcome shown in studies
of the SP-A KO mice.
The SP-A dose and time points, as noted above, were
based on a study where using the same conditions we
were able to restore tubular myelin to the lungs of KO
mice [121]. Moreover, based on measurements of SP-A
levels in the BAL of lungs of C57BL/6 mice, the dose
used was within the physiological range. A similar exo-
genous SP-A treatment has been reported [3,122],
although a number of other studies have used much
higher doses [20,123-125] that are clearly
supraphysiological.
The “restoration” of the global pattern of protein
synthesis in KO macrophages to that resembling WT
macrophages, when exogenous SP-A was given, was
remarkable. In 59 out of the 76 (78%) identified proteins
the change seen, compared to KO at 18 hr after exogen-
o u sS P - A ,w a sc o n s i s t e n tw i t ht h ed i f f e r e n c e sb e t w e e n
KO and WT. In other words, when WT levels were
lower than KO, the 18 hr SP-A value was lower than
KO and the opposite trend was apparent when WT
levels were greater than KO. However, this transition
from KO towards WT in response to SP-A treatment
was complex, because levels of some proteins (~1/3)
increased and others (~2/3) decreased in WT macro-
phages. This raised the possibility that with different
proteins SP-A may influence protein synthesis, metabo-
lism, and/or secretion by macrophages to achieve the
intracellular levels appropriate for baseline levels in the
macrophage.
Changes in the proteome of the treated versus
untreated mice could be the result of several different
regulatory mechanisms. SP-A may act directly on the
alveolar macrophage, through different receptors to
which it is known to bind [13,126-128], to directly influ-
ence the levels of expression of specific proteins. A sec-
ond potential mechanism would involve indirect effects
of SP-A on macrophage protein expression that result
from the direct influence of SP-A on other cells (such
as the type II cell), causing the synthesis and release of
mediators that, in turn, regulate the production of speci-
fic proteins by the alveolar macrophages in a paracrine
fashion. A third possibility is that SP-A exerts its influ-
ence on the alveolar macrophage proteome by regulat-
ing the release of regulatory molecules from one set of
alveolar macrophages that act on themselves or another
set of alveolar macrophages via either autocrine or para-
crine mechanisms, respectively. Regardless of whether
one or more of these possibilities contribute to the pro-
teome changes observed after SP-A treatment, what is
clear is that SP-A, either via its direct or indirect effects,
has a major impact on the protein expression pattern of
the alveolar macrophage. This impact includes signifi-
cant changes in more than half of the identified
proteins.
An important indirect factor in terms of SP-A regula-
tion of gene expression becomes apparent when we con-
sider one of our previous studies of the BAL proteome
of KO mice in which we postulated increased oxidative
stress in the absence of SP-A [26]. In the current study,
t h i sw o u l dl i k e l yb em a n i f e s t e db yc h a n g e si nt h e
expression of Nrf2-regulated proteins. Indeed, the Nrf2-
mediated oxidative stress response pathway was identi-
fied as a significant pathway in the present study. Con-
sistent with this notion are the observations made here
where nearly 1/3 of the identified proteins are Nrf2-
regulated, and are expressed at higher levels in KO than
in WT mice. In the WT and with SP-A treatment, levels
of expression of many of these proteins are significantly
reduced, suggesting a lessening of oxidative stress. Glu-
cose-6-phosphate dehydrogenase, a regulator of oxida-
tive stress [129] stands out as an example of this. This
enzyme is expressed at significantly higher levels in KO
than in WT mice and the 18 hr SP-A treatment reduces
it to levels significantly lower than KO baseline.
The most common phenotypic trait that has been
examined with the SP-A KO mice is increased suscept-
ibility to pneumonia. The simplest explanation for this
phenotype is that host defense against specific patho-
gens is compromised in the absence of SP-A and its
opsonic function. Indeed, replacement of SP-A in these
models has afforded some restoration of normal host
d e f e n s ef u n c t i o nb ya p p a r e n t l yi n c r e a s i n gp a t h o g e n
clearance [39,130]. Additional studies in which exogen-
ous SP-A has been administered to SP-A KO mice have
shown a diversity of functions or regulatory mechanisms
being restored. These include SP-A effects on the regu-
lation of allergic or inflammatory responses
[3,120,122,131,132] and other host defense molecules
[20,125], as well as the ability of exogenous SP-A to
restore tubular myelin, an extracellular form of surfac-
tant [121]. This diversity of effects, along with our BAL
proteomic studies [26,42], indicate that SP-A exerts a
pleiotropic effect in lung biology and/or health. The
observations from the present study not only provide
support for an SP-A pleiotropic effect on lung biology,
but identify many protein molecules and pathways
affected by the interaction of SP-A with the alveolar
macrophage. Together these put forward the notion that
the interaction of SP-A with the alveolar macrophage
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and maintaining the alveolar macrophage in a state of
“readiness” so that it can potentially successfully combat
injurious agents. Furthermore, based on the findings of
the present study where SP-A exhibits a broad and var-
ied impact on the alveolar macrophage proteome and
previous studies of the BAL proteome where the base-
line expression profile of SP-A KO and WT mice dif-
fered significantly [26,42], we postulate that these
differences are key to underlying mechanisms that are
responsible for the less favorable clinical outcome of the
SP-A KO mice with pneumonia [28,39,40,131] or bleo-
mycin-induced lung injury [120] where SP-A may be
dysfunctional due to its being oxidized. Thus, the collec-
tive evidence of the role of SP-A in the first line defense
of the alveolar surface depicts a diverse array of SP-A-
mediated functions that help maintain lung health, or
attenuate injury when the lung is challenged with var-
ious injurious agents, irritants, pathogens, and toxins
present in the external environment. Given the constant
exposure of the distal lung surface to all these external
harmful agents, it is important that mechanisms be in
place to remove these potentially damaging agents and
maintain normal lung structure. The alveolar macro-
phage and SP-A, both important components of innate
immunity, appear to play key roles in insuring that this
occurs.
SP-A has previously been shown to exert regulatory
effects on the production of several macrophage pro-
teins [7,14,16-21,125]. The present study shows for the
first time that an acute in vivo treatment with SP-A
under unstimulated, baseline conditions affected the
levels of significantly more and diverse macrophage pro-
teins than previously known. These include proteins
involved in macrophage motility, phagocytosis, neutrali-
zation of reactive oxidant species and other toxins,
removal of damaged tissue/proteins from the alveolus,
and other functions. These effects begin to be evident
by as early as 6 hr after exogenous SP-A treatment. By
18 hr after intratracheal SP-A treatment, the alveolar
macrophage proteome of the KO mouse becomes strik-
ingly similar to that of WT animals that have been con-
tinually and naturally exposed to SP-A. The diversity of
changed proteins broadly indicates that SP-A, under
basal conditions, plays a major role in alveolar macro-
phage “health” in terms of its potential ability to move
about and its “readiness” for pathogen elimination and
tissue repair.
The responses identified exhibited several consistent
patterns of protein expression. In one pattern the KO
mice and WT mice differed significantly from one
another (both increases and decreases) and intermediate
responses proceeding in the same direction were
observed at the two SP-A replacement time points. This
pattern was observed in 17 of the 20 proteins in which
KO and WT differed significantly (see Additional File
4). The obvious conclusion from this subset of
responses is that lack of continually available SP-A in
the KO mice alters protein expression and that acute
administration of exogenous SP-A leads toward a
restoration of the WT phenotype. Of the total of 76
proteins identified in the present study, 37 were proteins
with functions broadly related to actin and the cytoske-
leton, and of these 37 proteins, 11 differed significantly
between KO and WT and followed the pattern
described above where SP-A treatment changes expres-
sion levels toward those seen in WT. Many other pro-
teins in the actin-related/cytoskeletal group (n = 21 of
37) exhibited the same trend without achieving statisti-
cal significance. In most of the 32 responses made up by
these two groups (significant, n = 11 + not significant
but with a similar trend, n = 21), the time points after
SP-A replacement showed a logical progression from
KO to WT, indicating a trend toward restoration of the
WT phenotype by exogenous SP-A treatment. The
inclusion of so many of the significantly changing pro-
teins (n = 11) in the actin/cytoskeleton-related protein
group out of 20 significant changes between WT and
KO indicates that SP-A has a profound influence on
actin-related/cytoskeletal processes such as macrophage
motility and phagocytosis, potentially explaining the sus-
ceptibility of the KO mice to injury or infection. In vitro
studies have shown that an intact actin cytoskeleton, as
assessed by the use of cytochalasin D, an actin depoly-
merizing agent, is required for certain SP-A-mediated
processes [44] and in extrapulmonary tissues SP-A regu-
lates F-actin filament organization [45]. Although given
the importance of actin in cell motility, phagocytosis,
and endocytosis, it is not surprising that changes in
these proteins do occur, but the extent to which SP-A
affects the content of so many actin/cytoskeletal-related
proteins in vivo is remarkable. Significant changes in
protein content with a similar pattern were also seen in
several proteins involved in the inflammatory regulation
(n = 4) and protease/chaperone (n = 5) functional
groups.
The SP-A-dependent changes in actin-related/cytoske-
letal proteins may also be the nexus for the differences
in the other functional groups. As mentioned earlier,
many of the changing proteins are either known to be
regulated by Nrf2 or belong to functional classes known
to be Nrf2-regulated [133]. Keap 1, the repressor of
Nrf2, has been shown to regulate Nrf2 activity through
its binding to the actin cytoskeleton [119]. Similarly, a
role for the actin cytoskeleton has been described for
NF-B [134], a mechanism via which SP-A exerts some
of its functions [44,135,136]. These two transcriptional
regulators in addition to each interacting with the actin
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ious cells or tissues and a number of genes regulated by
both of them [137]. However, the interaction between
NF-B and Nrf2 is complex and may vary in different
systems or under different circumstances [138].
In addition, a number of proteins (n = 13) differed sig-
nificantly between KO mice and mice that had received
SP-A 18 hr earlier, even though no significant differ-
ences were observed between KO and WT mice. For
those proteins however, in most cases the trend in the
WT usually resembled that of the effect seen 18 hr after
SP-A. This subset of responses supports a scenario
where a robust acute response to SP-A is observed, with
some of the proteins exhibiting an overcompensation of
expression. For example, a number of protein spots (Fig-
ure 5) are increased at 6 hr but decreased at 18 hr after
treatment, as in the WT, although they may not have
not reached significance yet, indicating that some pro-
tein changes need a longer exposure to SP-A and/or
multiple doses of SP-A to reach the WT phenotype.
These responses included 6 proteins from the actin
group and 3 from the protease/chaperone group, indi-
cating that the acute SP-A treatment (like the continu-
ous presence of SP-A in WT) has a significant potential
to contribute to alterations in macrophage function.
Although statistical techniques such as gene set
enrichment analysis or hypergeometric distribution cal-
culations have been used with microarray data to deter-
mine whether changes in subsets of genes differ
significantly from a reference group or the overall popu-
lation in a specific group, these cannot be used here.
This is because of the relatively small data set examined
by gel-based proteomics and the comparatively large
numbers of proteins in our subsets that make up a sub-
stantial percentage of our overall population or refer-
ence group. For example 50% of the identified proteins
in our reference group were in our actin-related group
and 28% were included in the Nrf2-related proteins,
thereby violating the assumption that the analyzed
groups be independent of one another and precluding
the use of such methods in this study [139,140].
The large number of actin-related proteins with
altered levels of expression after SP-A treatment led us
to speculate that we would be able to validate the pro-
teomic findings with a preliminary examination of para-
meters related to actin cytoskeletal dynamics. In fact,
macrophages from SP-A KO mice treated with SP-A in
vitro were significantly larger than comparable control
cells and had lower amounts of F-actin, both at the 6 hr
time point used for this proteomic study (although total
gamma-actin levels were unchanged at this time point)
and at 1 hr, a time point where we have previously
demonstrated an SP-A-dependent enhancement of pha-
gocytosis by alveolar macrophages [29]. As SP-A
stimulation increased cell size, redistribution of the cor-
tical actin over a larger area likely contributes to the
decrease in the actin intensity per pixel. We speculate
that decreases in F-actin reflect cells that are more
actively remodeling their cytoskeletons, resulting in cells
of increased size. The larger size may indicate the avail-
ability of adequate amounts of excess membrane for
phagocytic or endocytic events to occur and the changes
in F-actin distribution likely reflect more dynamic actin
filaments with altered rates of actin polymerization/
depolymerization and branching. Thus, in the absence
of SP-A, macrophages appear to be small and “stiff”,
limiting their motility and phagocytic ability. However,
when SP-A is made available, in as little as one hour a
more dynamic actin cytoskeleton allows for enhanced
motility and ability to successfully locate and clear parti-
cles and pathogens. Our previously published observa-
tions on in vivo comparisons of SP-A KO and WT mice
in a model of pneumonia induced by Klebsiella pneumo-
niae [28] and on phagocytosis by alveolar macrophages
in vitro support this scenario [29].
This study was designed to allow us to study restora-
tion of the WT phenotype from KO alveolar macro-
phages after giving a single dose of SP-A and studying
its effect 6 hr and 18 hr later. Remarkably, the dose and
sampling times chosen restored levels of many of the
proteins we studied. It is likely that additional doses and
time points will further restore the phenotype by regu-
lating the expression of additional proteins with differ-
ent kinetics of translation and secretion. It is also highly
likely that SP-A regulation by continually present SP-A
(as in the WT state) or by multiple doses of SP-A will
differ somewhat from the pattern resulting from a single
acute dose, because in those cases a steady-state equili-
brium of the SP-A effects on the alveolar macrophage
proteome may be attained. Moreover, we had previously
proposed that SP-A “primes” the alveolar macrophage
[141] to prepare it to effectively respond to infectious or
toxic agents. The proteomic data presented here support
a role for SP-A under baseline conditions to drive an ill-
prepared “dysfunctional” alveolar macrophage from an
SP-A KO mouse towards readiness and effective host
defense as afforded by WT alveolar macrophages. More-
over, these data demonstrate the potential for the thera-
peutic use of a single dose of exogenous SP-A to
counter challenges due to injury or infection.
Conclusions
The observations in the present study show for the first
time that an acute in vivo treatment with SP-A affects,
under basal or unstimulated conditions, the expression
of diverse groups of proteins in the alveolar macro-
phage. The group of actin-related/cytoskeletal proteins
appeared to be a prominent one, indicating a significant
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related functions. This was further substantiated by
experiments showing significant changes in cell size and
cortical F-actin distribution 1 and 6 hr after SP-A treat-
ment. Furthermore, a significant number of the changed
proteins are likely to be Nrf2-regulated indicating a role
of SP-A in oxidative stress. We postulate that the SP-A-
mediated expression profile of the alveolar macrophage
places it in a state of “readiness” to successfully combat
various injurious insults. Published comparison studies
of SP-A KO and WT mice that showed a poorer out-
come in KO in response to various injurious agents sup-
port the concept of “readiness.” Therefore, SP-A appears
to be a critical factor for the “priming” and/or “readi-
ness” of the alveolar macrophage to carry out its innate
immune functions effectively and ensure lung health.
Materials and methods
Animals
This study was conducted using pathogen-free male WT
and SP-A KO male mice on the C57BL/6 genetic back-
ground. WT mice were obtained from Jackson Labora-
tories (Bar Harbor, ME). Breeder pairs of SP-A KO mice
had been obtained from Dr. Samuel Hawgood at the
University of California, San Francisco and were propa-
gated and raised under specific pathogen-free conditions
in a barrier facility at the Penn State College of Medi-
cine [142]. The SP-A KO mice and sentinel mice housed
i nt h es a m er o o ms h o w e dn oe v i d e n c eo fr e s p i r a t o r y
pathogens. The Institutional Animal Care and Use Com-
mittee at the Penn State College of Medicine approved
this study.
A total of 16, 25-34 g C57BL/6 WT and SP-A KO
mice were used to complete the proteomics study.
These were divided into four groups with 4 animals per
group: 1) SP-A KO control (baseline) mice that did not
receive any treatment; 2) SP-A KO mice that were trea-
ted with SP-A and sacrificed 6 hr after treatment; 3) SP-
A KO mice that were treated with SP-A and sacrificed
18 hr after SP-A treatment; and 4) WT control (base-
line) mice that did not receive any treatment.
SP-A preparation
SP-A was purified from the BAL fluid from normal
human lungs obtained from organ donors. The proto-
col was approved by the Penn State College of Medi-
cine Institutional Review Board. Donor lungs were
lavaged with 0.9% saline and the lavage fluid collected
and centrifuged at 150 × g for 10 min at 4°C to obtain
cell-free BAL. The SP-A was then purified by repeated
precipitation with 5 mM calcium chloride. The purity
of the preparation was checked by 1D-PAGE with sil-
ver stain and by Western blot and determined to be
greater than 99 percent pure. LPS content of the SP-A
preparation was measured with the QCL-1000 Limulus
Amebocyte Lysate assay (Lonza, Walkersville, MD).
The LPS content of a 1 μg sample of SP-A was below
the detectable limit of the assay (0.1 EU/ml) or < 500
fg/μgo fS P - A .
Treatment of mice with SP-A
Animals were anesthetized with an intramuscular injec-
tion of a mixture of Ketamine HCl (Ketaject, Phoenix
Pharmaceuticals Inc., St. Joseph, MO) and Xylazine
(XYLA-JECT, Phoenix Pharmaceuticals Inc., St. Joseph,
MO). Mice were suspended from their incisors and
intrapharyngeally instilled with 5 μgo fn o r m a lh u m a n
SP-A in 50 μL of 0.9% sodium chloride containing 2
mM calcium chloride. Mice were closely watched to
ensure that the entire dose was aspirated. We selected a
dose of 5 μg of SP-A/mouse based on our SP-A deter-
minations of total BAL SP-A from C57BL/6 mice (mean
3.2 μg ;n=9 ) .W eh a v ep r e v i o u s l yd e m o n s t r a t e dt h a t
using this dose of SP-A and a 6 hr time point, we were
able to detect tubular myelin in the BAL of SP-A KO
mice [121].
Collection of alveolar macrophages
Mice were anesthetized and subjected to BAL at inter-
vals of 6 hr and 18 hr following treatment with SP-A.
We chose 6 hr as our initial time point because we used
it successfully in a previous study examining tubular
myelin formation [121]. In addition, we postulated that
this time interval would be sufficient for new protein
synthesis to occur in response to SP-A treatment. The
18 hr time point was chosen to determine the longer
term effects of a single dose of SP-A, that could poten-
tially include the consequences of the indirect effects of
SP-A. BAL fluid was obtained by instilling PBS, 1 mM
EDTA into the lungs through a tracheal cannula using a
volume equal to 80% of lung vital capacity (5 × with 0.5
ml of PBS, 1 mM EDTA) for a total of 2.5 ml. For each
of the five washes, the fluid was instilled and withdrawn
3 times with chest massage during withdraw. The BAL
fluid was then centrifuged at 150 × g for 5 min at 4°C
and the cell pellet washed with 1 mL of PBS, 1 mM
EDTA. Total cell counts were performed using a hemo-
cytometer and cytocentrifuge preparations done to
obtain differential cell counts. The washed cells were
then centrifuged again and the pellets frozen at -80°C
for subsequent proteomic studies.
Preparation of samples for 2D-DIGE
Frozen macrophage pellets were lyophilized until com-
plete dryness and resuspended in 25 μLo fs t a n d a r dc e l l
lysis buffer (30 mM TrisHCl, 2 M thiourea, 7 M urea,
4% CHAPS, pH 8.5). Protein determinations were done
using the Bio-Rad Protein Assay (Bio-Rad, Hercules,
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mg/ml for CyDye labeling.
2D-DIGE labeling (minimal labeling) and electrophoresis
for 2D-DIGE
We have used this basic technique in previous studies
for other types of protein samples [26,46,143] but a
detailed account, including a number of modifications
and refinements appears below. Information about the
2D-DIGE study is provided in a form that complies with
the most recent version of Minimum Information About
a Proteomics Experiment-Gel Electrophoresis (MIAPE-
GE) standards currently under development (<http://
www.psidev.info/miape/MIAPE_GE_1_4.pdf >) by the
Human Proteome Organization Proteomics Standards
Initiative (see Additional File 1). Two sets of samples
from each group were prepared for minimal labeling
with CyDyes. Samples from each group were randomly
assigned to Cy3 or Cy5 to ensure no dye-based artifacts
in quantitation. A 20 μg aliquot of macrophage proteins
from each sample was labeled with either Cy3 or Cy5
(200 picomoles). A normalization pool was created by
combining equal amounts of protein from every sample
(16 samples) and an aliquot of the pool was labeled with
Cy2 (200 picomoles/20 μg). Equal amounts (20 μg) of
Cy3-labeled sample, Cy5-labeled sample, and Cy2-
labeled pool samples were mixed and applied to each
gel. An equal volume of 2X sample buffer (2 M
thiourea, 7 M urea, 2% IPG buffer (pH 4-7) and 1.2%
DeStreak reagent) was added to all samples to give a
final volume of 140 μl. Twenty-four cm, pH 4-7 gradient
Immobiline DryStrips (GE Healthcare) were rehydrated
f o r1 8h rw i t h4 5 0μl of rehydration buffer (DeStreak™
Rehydration Solution containing 0.5% IPG buffer (pH 4-
7). Proteins were subjected to isoelectric focusing on
rehydrated strips using an Ettan IPGphor 3 cup loading
manifold (GE Healthcare) following the manufacturer’s
instruction at 20°C and under mineral oil to prevent
evaporation. Proteins were focused using the following
voltages and times: 3 hr at 300 V (step and hold); 7 hr
at 1000 V (gradient); 4 hr at 8000 V (gradient); 4 hr at
8000 V (step and hold). After isoelectric focusing the
IEF strips were equilibrated in equilibration solution-1
(50 mM TrisHCl, 6 M urea, 30% glycerol, 2% sodium
dodecyl sulphate (SDS), 0.5% dithiothreitol) and equili-
bration solution-2 (50 mM TrisHCl, 6 M urea, 30% gly-
cerol, 2% SDS, 4.5% iodoacetamide) for 15 min,
respectively, and then applied to 10% polyacrylamide
gels (26 cm-w × 20 cm-h × 1 mm thick), sealed with
0.5% low melting point agarose containing bromophenol
blue in a buffer of 1X Tris/glycine/SDS buffer (25 mM
T r i s ,1 9 2m Mg l y c i n e ,0 . 1 %( W / V )S D S ,p H8 . 3 ) .P r o -
teins were then separated on the basis of molecular
weight using the Ettan DALTtwelve system (GE
Healthcare) at 5 W/gel for 30 min and then at 15 W/gel
at 20°C until the bromophenol blue dye front was 0.5
cm from the bottom of the gel (~4 hr).
For the preparative (picking) gel an aliquot of 450 μg
of sample was diluted with an equal volume of 2X sam-
ple buffer (2 M thiourea, 7 M urea, 2% IPG buffer (pH
4-7) and 1.2% DeStreak reagent) and then brought up to
av o l u m eo f4 5 0μl with rehydration buffer (DeStreak™
Rehydration Solution and 0.5% IPG buffer (pH 4-7)).
Proteins were focused using the following voltages and
times: 14 hr at 0 V (passive rehydration); 6 hr at 30 V
(active rehydration); 3 hr at 300 V (step and hold); 3 hr
at 600 V (gradient); 3 hr at 1000 V (gradient); 3 hr at
8000 V (gradient); 4 hr at 8000 V (step and hold). The
strip was then equilibrated as described above and
applied to a 10% polyacrylamide gel (26 cm-w × 20 cm-
h × 1 mm thick). For the preparative picking gel a single
plate for the gel plate sandwich was treated with Bind-
Silane solution (80% ethanol, 0.02% glacial acetic acid,
0.001% Bind-Silane) and had reference marker stickers
placed on it. After the completion of electrophoresis,
the plate that had not been silane-treated was removed
from the sandwich and the gel fixed overnight with 30%
ethanol, 7.5% glacial acetic acid. The preparative picking
gel was then stained with Deep Purple Total Protein
Stain (GE, Healthcare) for 2 hr.
Gel imaging, image analysis, and statistics
Information about the acquisition and processing of data
from the 2D-DIGE studies are provided in the form that
complies with the most recent version of the guidelines
established for Minimum Information about a Proteo-
mics Experiment-Gel Informatics (MIAPE-GI) currently
under development by the Human Proteome Organiza-
tion Proteomics Standards Initiative http://www.psidev.
info/files/miape-gi-v1.pdf (see Additional File 2). All
two-dimensional gels were imaged on a Typhoon 9410
fluorescent imager (GE Healthcare) at a resolution of
100 μm. Photomultiplier tube voltages were individually
set for each of the three colored lasers to ensure maxi-
mum, linear signals. The same voltages were used for all
the gels. The DIGE gels were imaged at three different
wavelengths (Cy2: 520 nm; Cy3: 580 nm; Cy5: 670 nm)
and the Deep Purple Total Protein Stain-stained gels
were imaged at 100 μm with a separate filter (610 nm).
Gel images were imported into the Progenesis Same-
Spots v4.0 program (Nonlinear Dynamics) for analysis
and their quality assessed by the program. Image quality
control with Progenesis SameSpots v4.0 involves check-
ing images for bit depth, color, manipulation prior to
analysis, proper file type, saturation, low dynamic range,
and stretched contrast. A reference gel with minimum
distortion and streaks was selected from the Cy2 gels.
Gel alignment was conducted automatically and then
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detection and spot matching across all the gels were
conducted automatically, and then spot matching was
checked and manually edited to ensure correct match-
ing. Data from all the spots included in analysis were
transported to Progenesis PG240 module of the Progen-
esis SameSpots v4.0 software for further analysis. Statis-
tical analysis was performed by ANOVA and by t-test to
confirm the level of significance among various groups.
Differences were considered statistically significant with
p < 0.05. Principal components analysis (PCA) was per-
formed and dendrograms plotted in the Statistics mod-
ule of Progenesis SameSpots v4.0 for the further analysis
of the patterns of protein expression and protein clus-
tering among groups.
For identified proteins having multiple isoforms, the
normalized volumes of all isoforms of a given protein
were added together and statistical analysis was per-
formed on the totals using Microsoft Excel.
Protein identification by mass spectrometry
We have used this procedurei np r e v i o u ss t u d i e sf o r
other types of protein samples [26,46,143] but a detailed
account, including many modifications and refinements
appears below. For identification of spots, all 791 pro-
tein spots from the experiment were picked from the
picking gel using a robot-directed spot picker (Ettan
Spot Picker, GE Healthcare). The picker head was cali-
brated using the reference stickers placed on the pre-
parative picking gel and the gel was picked and gel
plugs placed in bar-coded 96 well plates. All gel plugs
were washed twice with 200 μl of 200 mM ammonium
bicarbonate, 40% acetonitrile for 30 min at 37°C, lyophi-
lized to complete dryness and stored desiccated at 4°C
until processing. Plugs selected for processing were
rehydrated with 20 μlo f0 . 0 2μg/μl trypsin (Trypsin,
proteomics grade, Sigma, St. Louis, MO) for one hour at
room temperature. The trypsin solution was then
removed and replaced with 50 μl of 40 mM ammonium
bicarbonate, 9% acetonitrile and incubated overnight at
48°C. The overnight incubation solution was transferred
to new 96-well extraction plates and the plugs extracted
with 50 μl of 0.1% trifluoroacetic acid (TFA) for 30 min
at 37°C, followed by a second extraction with 50 μlo f
dH2O for 30 min at 37°C. All of the extracts for each
plug were pooled and then dried by lyophilization.
Dried extracts were then brought up in 200 μlo fd H 2O
and dried by lyophilization for a series of three cycles to
remove any remaining ammonium bicarbonate. The
final dried extracted proteins/peptides were brought up
in 20 μl of 0.5% TFA and desalted and concentrated
using C18 ZipTips (Millipore Corporation, Billerica,
MA). Tips were wetted with 10 μl of 100% acetonitrile
and equilibrated with 10 μl 0.1% TFA (pH < 4). Samples
were then drawn into ZipTip columns by aspirating for
10 cycles and then washed twice with 10 μl0 . 1 %T F A .
Peptides were then eluted from the column twice with
10 μl of 50% acetonitrile, 0.1% TFA. The ZipTip proce-
dure was performed four times for each extract to maxi-
mize peptide yield and the elutions were pooled,
lyophilized and resuspended in 2 μlo f5 0 %A c e t o n i t r i l e ,
1% TFA for MALDI plate spotting.
Peptides were analyzed by MALDI-ToF/ToF mass
spectrometry (5800 Proteomic Analyzer Applied Bio-
systems, Foster City, CA) in the Mass Spectrometry
Core at the Penn State University College of Medicine.
All of each ZipTip cleaned samples (1 μl at a time) was
applied onto a 384-well MALDI plate (Opti-TOF™
384 Well Insert, Applied Biosystems) and then 0.7 μl
of 2 mg/ml ACH cinnamic acid in 60:40 (acetonitrile:
water) was spotted on each well containing peptide. All
13-calibration wells on the MALDI plate were spotted
with (1:12 diluted) 4700 calibrant. Autolytic trypsin
peptides were also used to internally calibrate the spec-
tra to an accuracy of 20 ppm. Using the GPS Explorer
3.0 software (Applied Biosystems), the MS and MS/MS
data were submitted to the MASCOT search engine
using the NCBI non-redundant database and mouse
taxonomy for identification. The search parameters
included: trypsin digestion with a maximum of three
missed cleavages; fixed modifications, carbamidomethy-
lation; variable modifications, carbamylation, acetyla-
tion, deamidation, oxidation; peptide mass tolerance,
0.15 Da. MASCOT confidence interval scores of > 95%
combined with a ProteinPilot score of greater than 61
were considered as a positive protein identification. An
image of the reference gel is shown in Figure 1 with all
identified proteins circled and numbered. The
PANTHER database and the scientific literature were
used to provisionally assign molecular function and
biological process to each identified protein. We then
re-assigned the identified proteins to four broad func-
tional classes including: a) actin-related/cytoskeletal
proteins; b) proteins involved in protease balance/cha-
perone function; c) proteins involved in regulation of
inflammation: and d) proteins involved in regulatory/
differentiative processes. It should be noted that some
proteins are in more than one functional group. This
classification scheme was more inclusive than relying
solely on the biological function classification provided
by PANTHER and similar gene ontology databases. We
also used the Ingenuity Pathway Analysis program
(Ingenuity Systems, Redwood City, CA) to gain addi-
tional insight into the functional significance of the
observed changes. Protein names, accession numbers,
and the functional groups we assigned them to are
listed in Additional File 3 together with a list of sup-
porting references.
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AMs for F-actin staining
AMs were collected from the BAL fluid of male KO
mice as described earlier. AMs were washed 1X with
AM medium (RPMI-Hepes modification containing 2
mM L-glutamine and 1:100 antibiotic antimycotic solu-
tion). AMs were then resuspended in AM medium at 1
×1 0
5/ m La n d1m L( 1 0
5 AMs) plated to cover glasses
(No. 1 circles, 18 mm, 0.15 mm thick) in 12-well tissue
culture plates and allowed to adhere for 90 min at 37°C.
The medium was then removed and replaced with 1 mL
of fresh AM medium and the cells were cultured over-
night at 37°C. AMs were treated with SP-A for either
one or six hours by adding 5 μL( 5μg) of a 1 μg/μL
human SP-A stock solution in 10 mM Hepes (pH 7.5)
directly to the 1 mL of medium from the overnight
culture.
Alexa Fluor 488 phalloidin staining of F-Actin on AMs
After incubation with SP-A, AMs were washed 1X with
PBS at 37°C, fixed with 3.7% paraformaldehyde in PBS
for 10 min at 37°C and permeabilized with 0.5% Triton
in PBS for 5 min. After permeabilization, cells were
washed with PBS, incubated for 30 min in staining solu-
tion (PBS, 300 nM DAPI, 6.6 nM Alexa Fluor 488 phal-
loidin) and again washed with PBS 3X for 10 min.
Cover glasses containing the AMs were mounted to
slides using PBS containing 80% glycerol and 0.3% n-
propyl gallate, and then sealed using nail polish.
Image acquisition and data analysis
AMs were visualized using a Nikon TE-2000 PFS fluor-
escent microscope with a 60X (1.4 NA) phase contrast
lens with a 1.5× tube lens in place and the images cap-
tured using a Photometrics Coolsnap HQ2 digital cam-
era (0.07 μm/pixel) and saved as TIFF files. Exposure
time (200 ms) was kept constant for all images acquired.
Nikon NIS-Elements AR (version 3.0) software was used
to do both the image acquisition and data analysis. AMs
were analyzed by manually drawing a border for each
cell as well as copying an area of equal size to a location
immediately adjacent to each cell to be used for back-
ground subtraction. Data were then collected for area
(cell size), mean fluorescence intensity per pixel of cell
area, and the sum of the fluorescence intensity for all of
the pixels within a cell. Statistical analysis was per-
formed using Minitab and Excel.
Additional material
Additional file 1: MIAPE: Gel Electrophoresis. File containing
Minimum Information About a Proteomics Experiment-Gel
Electrophoresis in the format recommended by the Human Proteome
Organization Proteomic Standards Initiative.
Additional file 2: MIAPE: Gel Informatics. File containing Minimum
Information About a Proteomics Experiment-Gel Informatics in the format
recommended by the Human Proteome Organization Proteomic
Standards Initiative.
Additional file 3: Protein names and cross references to accession
numbers and categories. File containing a table that has the gel
numbers and names of all identified proteins. It contains both NCBI GI
numbers and Swiss Prot Accession numbers for all proteins, as well as
the designation for the functional group(s) to which each protein was
assigned. Reference numbers listed in the table are from the reference
list in the manuscript.
Additional file 4: Values for all identified alveolar macrophage
proteins with note of significant changes. File containing a table that
gives normalized volumes for all proteins for each individual group +/-
SD and indicates comparisons between groups that were significantly
different.
Acknowledgements and Funding
The authors thank Sanmei Hu and Susan DiAngelo for animal breeding and
genotyping and Anne Stanley in the Mass Spectrometry Core Facility at the
Penn State College of Medicine and Dr. Vernon Chinchilli in the Department
of Public Health Sciences for discussions about statistical methods. This
study was supported in part by R01 ES009882 from the National Institute of
Environmental Health Sciences.
Author details
1Center for Host defense, Inflammation, and Lung Disease (CHILD) Research
and Department of Pediatrics, The Pennsylvania State University College of
Medicine, Hershey, PA 17033, USA.
2Department of Cellular and Molecular
Physiology, The Pennsylvania State University College of Medicine, Hershey,
PA 17033, USA.
3Department of Obstetrics and Gynecology, The
Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Authors’ contributions
DSP and JF designed the study. DSP interpreted data and prepared the
manuscript. JF assisted with data interpretation, and participated in
manuscript preparation. TMU treated mice, collected samples, ran gels,
prepared mass spec samples, evaluated mass spec data, did preliminary
analysis of proteomic data, and participated in the writing of the manuscript.
OAQ prepared the cell samples for the microscopy experiments, collected
images, and performed the image analyses. CMY participated in design of
actin experiments and interpreted actin data. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 February 2011 Accepted: 28 October 2011
Published: 28 October 2011
References
1. Hickling TP, Malhotra R, Bright H, McDowell W, Blair ED, Sim RB: Lung
surfactant protein A provides a route of entry for respiratory syncytial
virus into host cells. Viral Immunol 2000, 13:125-135.
2. Madan T, Kishore U, Shah A, Eggleton P, Strong P, Wang JY, Aggrawal SS,
Sarma PU, Reid KBM: Lung surfactant proteins A and D can inhibit
specific IgE binding to the allergens of Aspergillus fumigatus and block
allergen-induced histamine release from human basophils. Clin exp
Immunol 1997, 110:241-249.
3. Madan T, Kishore U, Singh M, Strong P, Clark H, Hussain EM, Reid KB,
Sarma PU: Surfactant proteins A and D protect mice against pulmonary
hypersensitivity induced by Aspergillus fumigatus antigens and
allergens. J Clin Invest 2001, 107:467-475.
4. Madan T, Reid KB, Clark H, Singh M, Nayak A, Sarma PU, Hawgood S,
Kishore U: Susceptibility of mice genetically deficient in SP-A or SP-D
gene to invasive pulmonary aspergillosis. Mol Immunol 2010,
47:1923-1930.
Phelps et al. Proteome Science 2011, 9:67
http://www.proteomesci.com/content/9/1/67
Page 17 of 215. Malhotra R, Haurum J, Thiel S, Jensenius JC, Sim RB: Pollen grains bind to
lung alveolar type II cells (A549) via lung surfactant protein A (SP-A).
Biosci Rep 1993, 13:79-90.
6. Kremlev SG, Phelps DS: Surfactant protein A stimulation of inflammatory
cytokine and immunoglobulin production. Am J Physiol 1994, 267:
L712-L719.
7. Kremlev SG, Umstead TM, Phelps DS: Surfactant protein A regulates
cytokine production in the monocytic cell line THP-1. Am J Physiol 1997,
272:L996-1004.
8. Wang G, Phelps DS, Umstead TM, Floros J: Human SP-A protein variants
derived from one or both genes stimulate TNF-alpha production in the
THP-1 cell line. Am J Physiol Lung Cell Mol Physiol 2000, 278:L946-L954.
9. Wang H, Tracey KJ: Tumor necrosis factor, interleukin-6, macrophage
migration inhibitory factor, and macrophage inflammatory protein-1 in
inflammation. In Inflammation: Basic Principles and Clinical Correlates.. 3
edition. Edited by: Gallin JI, Snyderman R. Philadelphia: Lippincott Williams
1999:471-486.
10. Meloni F, Alberti A, Bulgheroni A, Lupi A, Paschetto E, Marone BA, Rodi G,
Fietta A, Luisetti M, Baritussio A: Surfactant apoprotein A modulates
interleukin-8 and monocyte chemotactic peptide-1 production. Eur Respir
J 2002, 19:1128-1135.
11. Borron PJ, Crouch EC, Lewis JF, Wright JR, Possmayer F, Fraher LJ:
Recombinant rat surfactant-associated protein D inhibits human T
lymphocyte proliferation and IL-2 production. J Immunol 1998,
161:4599-4603.
12. Alcorn JF, Wright JR: Surfactant protein A inhibits alveolar macrophage
cytokine production by CD14-independent pathway. Am J Physiol Lung
Cell Mol Physiol 2004, 286:L129-L136.
13. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE,
Henson PM: By binding SIRPalpha or calreticulin/CD91, lung collectins
act as dual function surveillance molecules to suppress or enhance
inflammation. Cell 2003, 115:13-23.
14. Wang G, Umstead TM, Phelps DS, Al Mondhiry H, Floros J: The effect of
ozone exposure on the ability of human surfactant protein A variants to
stimulate cytokine production. Environ Health Perspect 2002, 110:79-84.
15. Huang W, Wang G, Phelps DS, Al Mondhiry H, Floros J: Combined SP-A-
bleomycin effect on cytokines by THP-1 cells: impact of surfactant lipids
on this effect. Am J Physiol Lung Cell Mol Physiol 2002, 283:L94-L102.
16. Huang W, Wang G, Phelps DS, Al Mondhiry H, Floros J: Human SP-A
genetic variants and bleomycin-induced cytokine production by THP-1
cells: effect of ozone-induced SP-A oxidation. Am J Physiol Lung Cell Mol
Physiol 2004, 286:L546-L553.
17. Kuronuma K, Sano H, Kato K, Kudo K, Hyakushima N, Yokota S, Takahashi H,
Fujii N, Suzuki H, Kodama T, Abe S, Kuroki Y: Pulmonary surfactant protein
A augments the phagocytosis of Streptococcus pneumoniae by alveolar
macrophages through a casein kinase 2-dependent increase of cell
surface localization of scavenger receptor A. J Biol Chem 2004,
279:21421-21430.
18. Beharka AA, Gaynor CD, Kang BK, Voelker DR, McCormack FX,
Schlesinger LS: Pulmonary surfactant protein A up-regulates activity of
the mannose receptor, a pattern recognition receptor expressed on
human macrophages. J Immunol 2002, 169:3565-3573.
19. Kremlev SG, Phelps DS: Effect of SP-A and surfactant lipids on expression
of cell surface markers in the THP-1 monocytic cell line. Am J Physiol
1997, 272:L1070-L1077.
20. Gil M, McCormack FX, LeVine AM: Surfactant protein A modulates cell
surface expression of CR3 on alveolar macrophages and enhances CR3-
mediated phagocytosis. J Biol Chem 2009, 284:7495-7504.
21. Henning LN, Azad AK, Parsa KV, Crowther JE, Tridandapani S, Schlesinger LS:
Pulmonary surfactant protein A regulates TLR expression and activity in
human macrophages. J Immunol 2008, 180:7847-7858.
22. Blanco O, Catala A: Surfactant protein A inhibits the non-enzymatic lipid
peroxidation of porcine lung surfactant. Prostaglandins Leukot Essent Fatty
Acids 2001, 65:185-190.
23. Bridges JP, Davis HW, Damodarasamy M, Kuroki Y, Howles G, Hui DY,
McCormack FX: Pulmonary surfactant proteins A and D are potent
endogenous inhibitors of lipid peroxidation and oxidative cellular injury.
J Biol Chem 2000, 275:38848-38855.
24. Gil HW, Oh MH, Woo KM, Lee EY, Oh MH, Hong SY: Relationship between
pulmonary surfactant protein and lipid peroxidation in lung injury due
to paraquat intoxication in rats. Korean J Intern Med 2007, 22:67-72.
25. Terrasa AM, Guajardo MH, de Armas SE, Catala A: Pulmonary surfactant
protein A inhibits the lipid peroxidation stimulated by linoleic acid
hydroperoxide of rat lung mitochondria and microsomes. Biochim
Biophys Acta 2005, 1735:101-110.
26. Haque R, Umstead TM, Freeman WM, Floros J, Phelps DS: The impact of
surfactant protein-A on ozone-induced changes in the mouse
bronchoalveolar lavage proteome. Proteome Sci 2009, 7:12.
27. Mikerov AN, Gan X, Umstead TM, Miller L, Chinchilli VM, Phelps DS, Floros J:
Sex differences in the impact of ozone on survival and alveolar
macrophage function of mice after Klebsiella pneumoniae infection.
Respir Res 2008, 9:24.
28. Mikerov AN, Haque R, Gan X, Guo X, Phelps DS, Floros J: Ablation of SP-A
has a negative impact on the susceptibility of mice to Klebsiella
pneumoniae infection after ozone exposure: sex differences. Respir Res
2008, 9:77.
29. Mikerov AN, Umstead TM, Gan X, Huang W, Guo X, Wang G, Phelps DS,
Floros J: Impact of ozone exposure on the phagocytic activity of human
surfactant protein A (SP-A) and SP-A variants. Am J Physiol Lung Cell Mol
Physiol 2008, 294:L121-L130.
30. Mikerov AN, Umstead TM, Huang W, Liu W, Phelps DS, Floros J: SP-A1 and
SP-A2 variants differentially enhance association of Pseudomonas
aeruginosa with rat alveolar macrophages. Am J Physiol Lung Cell Mol
Physiol 2005, 288:L150-L158.
31. Kuzmenko AI, Wu H, McCormack FX: Pulmonary collectins selectively
permeabilize model bacterial membranes containing rough
lipopolysaccharide. Biochemistry 2006, 45:2679-2685.
32. Kuzmenko AI, Wu H, Wan S, McCormack FX: Surfactant protein A is a
principal and oxidation-sensitive microbial permeabilizing factor in the
alveolar lining fluid. J Biol Chem 2005, 280:25913-25919.
33. Hickman-Davis JM, Gibbs-Erwin J, Lindsey JR, Matalon S: Role of surfactant
protein-a in nitric oxide production and Mycoplasma killing in congenic
C57BL/6 mice. Am J Respir Cell Mol Biol 2004, 30:319-325.
34. Brinker KG, Garner H, Wright JR: Surfactant protein A modulates the
differentiation of murine bone marrow-derived dendritic cells. Am J
Physiol Lung Cell Mol Physiol 2003, 284:L232-L241.
35. Yang S, Milla C, Panoskaltsis-Mortari A, Ingbar DH, Blazar BR, Haddad IY:
Human surfactant protein A suppresses T cell-dependent inflammation
and attenuates the manifestations of idiopathic pneumonia syndrome in
mice. Am J Respir Cell Mol Biol 2001, 24:527-536.
36. Atochina EN, Beck JM, Preston AM, Haczku A, Tomer Y, Scanlon ST,
Fusaro T, Casey J, Hawgood S, Gow AJ, Beers MF: Enhanced lung injury
and delayed clearance of Pneumocystis carinii in surfactant protein A-
deficient mice: attenuation of cytokine responses and reactive oxygen-
nitrogen species. Infect Immun 2004, 72:6002-6011.
37. Hickman-Davis JM, Fang FC, Nathan C, Shepherd VL, Voelker DR, Wright JR:
Lung surfactant and reactive oxygen-nitrogen species: antimicrobial
activity and host-pathogen interactions. Am J Physiol Lung Cell Mol Physiol
2001, 281:L517-L523.
38. LeVine AM, Kurak KE, Bruno MD, Stark JM, Whitsett JA, Korfhagen TR:
Surfactant protein-A-deficient mice are susceptible to Pseudomonas
aeruginosa infection. Am J Respir Cell Mol Biol 1998, 19:700-708.
39. LeVine AM, Kurak KE, Wright JR, Watford WT, Bruno MD, Ross GF,
Whitsett JA, Korfhagen TR: Surfactant protein-A binds group B
streptococcus enhancing phagocytosis and clearance from lungs of
surfactant protein-A-deficient mice. Am J Respir Cell Mol Biol 1999,
20:279-286.
40. LeVine AM, Gwozdz J, Stark J, Bruno M, Whitsett J, Korfhagen T: Surfactant
protein-A enhances respiratory syncytial virus clearance in vivo. J Clin
Invest 1999, 103:1015-1021.
41. Linke MJ, Harris CE, Korfhagen TR, McCormack FX, Ashbaugh AD, Steele P,
Whitsett JA, Walzer PD: Immunosuppressed surfactant protein A-deficient
mice have increased susceptibility to Pneumocystis carinii infection. J
Infect Dis 2001, 183:943-952.
42. Ali M, Umstead TM, Haque R, Mikerov AN, Freeman WM, Floros J,
Phelps DS: Differences in the BAL proteome after Klebsiella pneumoniae
infection in wild type and SP-A-/- mice. Proteome Sci 2010, 8:34.
43. Guth AM, Janssen WJ, Bosio CM, Crouch EC, Henson PM, Dow SW: Lung
environment determines unique phenotype of alveolar macrophages.
Am J Physiol Lung Cell Mol Physiol 2009, 296:L936-L946.
Phelps et al. Proteome Science 2011, 9:67
http://www.proteomesci.com/content/9/1/67
Page 18 of 2144. Moulakakis C, Stamme C: Role of clathrin-mediated endocytosis of
surfactant protein A by alveolar macrophages in intracellular signaling.
Am J Physiol Lung Cell Mol Physiol 2009, 296:L430-L441.
45. Breuiller-Fouche M, Dubois O, Sediki M, Garcia-Verdugo I, Palaniyar N,
Tanfin Z, Chissey A, Cabrol D, Charpigny G, Mehats C: Secreted surfactant
protein A from fetal membranes induces stress fibers in cultured human
myometrial cells. Am J Physiol Endocrinol Metab 2010, 298:E1188-E1197.
46. Umstead TM, Freeman WM, Chinchilli VM, Phelps DS: Age-related changes
in the expression and oxidation of bronchoalveolar lavage proteins in
the rat. Am J Physiol Lung Cell Mol Physiol 2009, 296:L14-L29.
47. Delanote V, Vandekerckhove J, Gettemans J: Plastins: versatile modulators
of actin organization in (patho)physiological cellular processes. Acta
Pharmacol Sin 2005, 26:769-779.
48. Wang X, Tomso DJ, Chorley BN, Cho HY, Cheung VG, Kleeberger SR,
Bell DA: Identification of polymorphic antioxidant response elements in
the human genome. Hum Mol Genet 2007, 16:1188-1200.
49. Mullins RD, Heuser JA, Pollard TD: The interaction of Arp2/3 complex with
actin: nucleation, high affinity pointed end capping, and formation of
branching networks of filaments. Proc Natl Acad Sci USA 1998,
95:6181-6186.
50. Cooper JA, Sept D: New insights into mechanism and regulation of actin
capping protein. Int Rev Cell Mol Biol 2008, 267:183-206.
51. Setiyono A, Budiyati AD, Purwantomo S, Anggelia MR, Fanany I,
Wibowo GA, Bachtiar I, Utama A, Tai S: Immunoregulatory effects of AFP
domains on monocyte-derived dendritic cell function. BMC Immunol
2011, 12:4.
52. Morel E, Parton RG, Gruenberg J: Annexin A2-dependent polymerization
of actin mediates endosome biogenesis. Dev Cell 2009, 16:445-457.
53. Rescher U, Ludwig C, Konietzko V, Kharitonenkov A, Gerke V: Tyrosine
phosphorylation of annexin A2 regulates Rho-mediated actin
rearrangement and cell adhesion. J Cell Sci 2008, 121:2177-2185.
54. Laumonnier Y, Syrovets T, Burysek L, Simmet T: Identification of the
annexin A2 heterotetramer as a receptor for the plasmin-induced
signaling in human peripheral monocytes. Blood 2006, 107:3342-3349.
55. Jeon YJ, Kim DH, Jung H, Chung SJ, Chi SW, Cho S, Lee SC, Park BC,
Park SG, Bae KH: Annexin A4 interacts with the NF-kappaB p50 subunit
and modulates NF-kappaB transcriptional activity in a Ca2+-dependent
manner. Cell Mol Life Sci 2010, 67:2271-2281.
56. Potter DA, Tirnauer JS, Janssen R, Croall DE, Hughes CN, Fiacco KA, Mier JW,
Maki M, Herman IM: Calpain regulates actin remodeling during cell
spreading. J Cell Biol 1998, 141:647-662.
57. Franco SJ, Huttenlocher A: Regulating cell migration: calpains make the
cut. J Cell Sci 2005, 118:3829-3838.
58. Kostyukova AS: Capping complex formation at the slow-growing end of
the actin filament. Biochemistry (Mosc) 2008, 73:1467-1472.
59. Bewley MA, Marriott HM, Tulone C, Francis SE, Mitchell TJ, Read RC, Chain B,
Kroemer G, Whyte MK, Dockrell DH: A cardinal role for cathepsin d in co-
ordinating the host-mediated apoptosis of macrophages and killing of
pneumococci. PLoS Pathog 2011, 7:e1001262.
60. Kitteringham NR, Abdullah A, Walsh J, Randle L, Jenkins RE, Sison R,
Goldring CE, Powell H, Sanderson C, Williams S, Higgins L, Yamamoto M,
Hayes J, Park BK: Proteomic analysis of Nrf2 deficient transgenic mice
reveals cellular defence and lipid metabolism as primary Nrf2-
dependent pathways in the liver. J Proteomics 2010, 73:1612-1631.
61. Lundin VF, Leroux MR, Stirling PC: Quality control of cytoskeletal proteins
and human disease. Trends Biochem Sci 2010, 35:288-297.
62. Brackley KI, Grantham J: Subunits of the chaperonin CCT interact with F-
actin and influence cell shape and cytoskeletal assembly. Exp Cell Res
2010, 316:543-553.
63. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH,
Takyar S, Elias JA: Role of chitin and chitinase/chitinase-like proteins in
inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011,
73:479-501.
64. Eismann T, Huber N, Shin T, Kuboki S, Galloway E, Wyder M, Edwards MJ,
Greis KD, Shertzer HG, Fisher AB, Lentsch AB: Peroxiredoxin-6 protects
against mitochondrial dysfunction and liver injury during ischemia-
reperfusion in mice. Am J Physiol Gastrointest Liver Physiol 2009, 296:
G266-G274.
65. Singh H, Cousin MA, Ashley RH: Functional reconstitution of mammalian
‘chloride intracellular channels’ CLIC1, CLIC4 and CLIC5 reveals
differential regulation by cytoskeletal actin. FEBS J 2007, 274:6306-6316.
66. Averaimo S, Milton RH, Duchen MR, Mazzanti M: Chloride intracellular
channel 1 (CLIC1): Sensor and effector during oxidative stress. FEBS Lett
2010, 584:2076-2084.
67. Chuang JZ, Chou SY, Sung CH: Chloride intracellular channel 4 is critical
for the epithelial morphogenesis of RPE cells and retinal attachment.
Mol Biol Cell 2010, 21:3017-3028.
68. Hu R, Xu C, Shen G, Jain MR, Khor TO, Gopalkrishnan A, Lin W, Reddy B,
Chan JY, Kong AN: Identification of Nrf2-regulated genes induced by
chemopreventive isothiocyanate PEITC by oligonucleotide microarray.
Life Sci 2006, 79:1944-1955.
69. Cuzzocrea S, Genovese T, Failla M, Vecchio G, Fruciano M, Mazzon E, Di
Paola R, Muia C, La Rosa C, Crimi N, Rizzarelli E, Vancheri C: Protective
effect of orally administered carnosine on bleomycin-induced lung
injury. Am J Physiol Lung Cell Mol Physiol 2007, 292:L1095-L1104.
70. Esser J, Rakonjac M, Hofmann B, Fischer L, Provost P, Schneider G,
Steinhilber D, Samuelsson B, Radmark O: Coactosin-like protein functions
as a stabilizing chaperone for 5-lipoxygenase: role of tryptophan 102.
Biochem J 2010, 425:265-274.
71. Dai H, Huang W, Xu J, Yao B, Xiong S, Ding H, Tang Y, Liu H, Wu J, Shi Y:
Binding model of human coactosin-like protein with filament actin
revealed by mutagenesis. Biochim Biophys Acta 2006, 1764:1688-1700.
72. Keller A, Peltzer J, Carpentier G, Horvath I, Olah J, Duchesnay A, Orosz F,
Ovadi J: Interactions of enolase isoforms with tubulin and microtubules
during myogenesis. Biochim Biophys Acta 2007, 1770:919-926.
73. Wygrecka M, Marsh LM, Morty RE, Henneke I, Guenther A, Lohmeyer J,
Markart P, Preissner KT: Enolase-1 promotes plasminogen-mediated
recruitment of monocytes to the acutely inflamed lung. Blood 2009,
113:5588-5598.
74. Zanelli CF, Valentini SR: Is there a role for eIF5A in translation? Amino
Acids 2007, 33:351-358.
75. Olson EN, Nordheim A: Linking actin dynamics and gene transcription to
drive cellular motile functions. Nat Rev Mol Cell Biol 2010, 11:353-365.
76. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW:
Modulation of gene expression by cancer chemopreventive
dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel
gene clusters for cell survival. J Biol Chem 2003, 278:8135-8145.
77. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA: Identification of the NF-
E2-related factor-2-dependent genes conferring protection against
oxidative stress in primary cortical astrocytes using oligonucleotide
microarray analysis. J Biol Chem 2003, 278:12029-12038.
78. Fernandez JR, Byrne B, Firestein BL: Phylogenetic analysis and molecular
evolution of guanine deaminases: from guanine to dendrites. J Mol Evol
2009, 68:227-235.
79. Kampinga HH, Hageman J, Vos MJ, Kubota H, Tanguay RM, Bruford EA,
Cheetham ME, Chen B, Hightower LE: Guidelines for the nomenclature of
the human heat shock proteins. Cell Stress Chaperones 2009, 14:105-111.
80. Niture SK, Jaiswal AK: Hsp90 interaction with INrf2(Keap1) mediates
stress-induced Nrf2 activation. J Biol Chem 2010, 285:36865-36875.
81. Wisniewska M, Karlberg T, Lehtio L, Johansson I, Kotenyova T, Moche M,
Schuler H: Crystal structures of the ATPase domains of four human
Hsp70 isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B’,
and HSPA5/BiP/GRP78. PLoS One 2010, 5:e8625.
82. Pockley AG, Muthana M, Calderwood SK: The dual immunoregulatory
roles of stress proteins. Trends Biochem Sci 2008, 33:71-79.
83. Madore AM, Perron S, Turmel V, Laviolette M, Bissonnette EY, Laprise C:
Alveolar macrophages in allergic asthma: An expression signature
characterized by heat shock protein pathways. Hum Immunol 2009.
84. Thomas SG, Calaminus SD, Auger JM, Watson SP, Machesky LM: Studies on
the actin-binding protein HS1 in platelets. BMC Cell Biol 2007, 8:46.
85. Burkhardt JK, Carrizosa E, Shaffer MH: The actin cytoskeleton in T cell
activation. Annu Rev Immunol 2008, 26:233-259.
86. Gao JL, Guillabert A, Hu J, Le Y, Urizar E, Seligman E, Fang KJ, Yuan X,
Imbault V, Communi D, Wang JM, Parmentier M, Murphy PM, Migeotte I:
F2L, a peptide derived from heme-binding protein, chemoattracts
mouse neutrophils by specifically activating Fpr2, the low-affinity N-
formylpeptide receptor. J Immunol 2007, 178:1450-1456.
87. Li H, Liu J: Identification of heterogeneous nuclear ribonucleoprotein K
as a transactivator for human low density lipoprotein receptor gene
transcription. J Biol Chem 2010, 285:17789-17797.
88. Tsan MF: Heat shock proteins and high mobility group box 1 protein
lack cytokine function. J Leukoc Biol 2011.
Phelps et al. Proteome Science 2011, 9:67
http://www.proteomesci.com/content/9/1/67
Page 19 of 2189. Goh ET, Pardo OE, Michael N, Niewiarowski A, Totty N, Volkova D,
Tsaneva IR, Seckl MJ, Gout I: Involvement of heterogeneous
ribonucleoprotein F in the regulation of cell proliferation via the
mammalian target of rapamycin/S6 kinase 2 pathway. J Biol Chem 2010,
285:17065-17076.
90. Yang Y, Gozen O, Watkins A, Lorenzini I, Lepore A, Gao Y, Vidensky S,
Brennan J, Poulsen D, Won PJ, Li JN, Robinson MB, Rothstein JD:
Presynaptic regulation of astroglial excitatory neurotransmitter
transporter GLT1. Neuron 2009, 61:880-894.
91. Caulin C, Ware CF, Magin TM, Oshima RG: Keratin-dependent, epithelial
resistance to tumor necrosis factor-induced apoptosis. J Cell Biol 2000,
149:17-22.
92. Traweek ST, Liu J, Battifora H: Keratin gene expression in non-epithelial
tissues. Detection with polymerase chain reaction. Am J Pathol 1993,
142:1111-1118.
93. Waseem A, Alam Y, Dogan B, White KN, Leigh IM, Waseem NH: Isolation,
sequence and expression of the gene encoding human keratin 13. Gene
1998, 215:269-279.
94. Herrmann C, Golkaramnay E, Inman E, Rome L, Volknandt W: Recombinant
major vault protein is targeted to neuritic tips of PC12 cells. J Cell Biol
1999, 144:1163-1172.
95. Honnappa S, Gouveia SM, Weisbrich A, Damberger FF, Bhavesh NS,
Jawhari H, Grigoriev I, van Rijssel FJ, Buey RM, Lawera A, Jelesarov I,
Winkler FK, Wuthrich K, Akhmanova A, Steinmetz MO: An EB1-binding
motif acts as a microtubule tip localization signal. Cell 2009, 138:366-376.
96. Hsu CY, Yung BY: Down-regulation of nucleophosmin/B23 during retinoic
acid-induced differentiation of human promyelocytic leukemia HL-60
cells. Oncogene 1998, 16:915-923.
97. Watanabe N, Iwamura T, Shinoda T, Fujita T: Regulation of NFKB1 proteins
by the candidate oncoprotein BCL-3: generation of NF-kappaB
homodimers from the cytoplasmic pool of p50-p105 and nuclear
translocation. EMBO J 1997, 16:3609-3620.
98. Wang J, Jiao H, Stewart TL, Shankowsky HA, Scott PG, Tredget EE: Increased
severity of bleomycin-induced skin fibrosis in mice with leukocyte-
specific protein 1 deficiency. J Invest Dermatol 2008, 128:2767-2776.
99. Li W, Febbraio M, Reddy SP, Yu DY, Yamamoto M, Silverstein RL: CD36
participates in a signaling pathway that regulates ROS formation in
murine VSMCs. J Clin Invest 2010, 120:3996-4006.
100. Natarajan R, Salloum FN, Fisher BJ, Smithson L, Almenara J, Fowler AA III:
Prolyl hydroxylase inhibition attenuates post-ischemic cardiac injury via
induction of endoplasmic reticulum stress genes. Vascul Pharmacol 2009,
51:110-118.
101. Ito Y, Kondo E, Demachi-Okamura A, Akatsuka Y, Tsujimura K, Tanimoto M,
Morishima Y, Takahashi T, Kuzushima K: Three immunoproteasome-
associated subunits cooperatively generate a cytotoxic T-lymphocyte
epitope of Epstein-Barr virus LMP2A by overcoming specific structures
resistant to epitope liberation. J Virol 2006, 80:883-890.
102. Hopitzan A, Himmelbauer H, Spevak W, Castanon MJ: The mouse Psma1
gene coding for the alpha-type C2 proteasome subunit: structural and
functional analysis, mapping, and colocalization with Pde3b on mouse
chromosome 7. Genomics 2000, 66:313-323.
103. Jung KA, Kwak MK: The Nrf2 system as a potential target for the
development of indirect antioxidants. Molecules 2010, 15:7266-7291.
104. Akama K, Horikoshi T, Sugiyama A, Nakahata S, Akitsu A, Niwa N, Intoh A,
Kakui Y, Sugaya M, Takei K, Imaizumi N, Sato T, Matsumoto R, Iwahashi H,
Kashiwabara S, Baba T, Nakamura M, Toda T: Protein disulfide isomerase-
P5, down-regulated in the final stage of boar epididymal sperm
maturation, catalyzes disulfide formation to inhibit protein function in
oxidative refolding of reduced denatured lysozyme. Biochim Biophys Acta
2010, 1804:1272-1284.
105. Grune T, Reinheckel T, Li R, North JA, Davies KJ: Proteasome-dependent
turnover of protein disulfide isomerase in oxidatively stressed cells. Arch
Biochem Biophys 2002, 397:407-413.
106. Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC,
Sonenberg N: mRNA helicases: the tacticians of translational control. Nat
Rev Mol Cell Biol 2011, 12:235-245.
107. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA,
Murphy TH: Coordinate regulation of glutathione biosynthesis and
release by Nrf2-expressing glia potently protects neurons from oxidative
stress. J Neurosci 2003, 23:3394-3406.
108. Liu P, Bartz R, Zehmer JK, Ying YS, Zhu M, Serrero G, Anderson RG: Rab-
regulated interaction of early endosomes with lipid droplets. Biochim
Biophys Acta 2007, 1773:784-793.
109. Rivero F, Illenberger D, Somesh BP, Dislich H, Adam N, Meyer AK: Defects
in cytokinesis, actin reorganization and the contractile vacuole in cells
deficient in RhoGDI. EMBO J 2002, 21:4539-4549.
110. Benarafa C, Cooley J, Zeng W, Bird PI, Remold-O’Donnell E: Characterization
of four murine homologs of the human ov-serpin monocyte neutrophil
elastase inhibitor MNEI (SERPINB1). J Biol Chem 2002, 277:42028-42033.
111. Fang L, Min L, Lin Y, Ping G, Rui W, Ying Z, Xi W, Ting H, Li L, Ke D,
Jihong R, Huizhong Z: Downregulation of stathmin expression is
mediated directly by Egr1 and associated with p53 activity in lung
cancer cell line A549. Cell Signal 2010, 22:166-173.
112. Eng EW, Bettio A, Ibrahim J, Harrison RE: MTOC reorientation occurs
during FcgammaR-mediated phagocytosis in macrophages. Mol Biol Cell
2007, 18:2389-2399.
113. Zuo S, Xue Y, Tang S, Yao J, Du R, Yang P, Chen X: 14-3-3 epsilon
dynamically interacts with key components of mitogen-activated
protein kinase signal module for selective modulation of the TNF-alpha-
induced time course-dependent NF-kappaB activity. J Proteome Res 2010,
9:3465-3478.
114. Bodas M, Min T, Vij N: Early-age-related changes in proteostasis augment
immunopathogenesis of sepsis and acute lung injury. PLoS One 2010, 5:
e15480.
115. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM: Vimentin is secreted
by activated macrophages. Nat Cell Biol 2003, 5:59-63.
116. Varin A, Gordon S: Alternative activation of macrophages: immune
function and cellular biology. Immunobiol 2009, 214:630-641.
117. Jin M, Opalek JM, Marsh CB, Wu HM: Proteome comparison of alveolar
macrophages with monocytes reveals distinct protein characteristics. Am
J Respir Cell Mol Biol 2004, 31:322-329.
118. Mosser DM, Edwards JP: Exploring the full spectrum of macrophage
activation. Nat Rev Immunol 2008, 8:958-969.
119. Kang MI, Kobayashi A, Wakabayashi N, Kim SG, Yamamoto M: Scaffolding
of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key
regulator of cytoprotective phase 2 genes. Proc Natl Acad Sci USA 2004,
101:2046-2051.
120. Goto H, Ledford JG, Mukherjee S, Noble PW, Williams KL, Wright JR: The
role of surfactant protein A in bleomycin-induced acute lung injury. Am
J Respir Crit Care Med 2010, 181:1336-1344.
121. Wang G, Guo X, DiAngelo S, Thomas NJ, Floros J: Humanized SFTPA1 and
SFTPA2 transgenic mice reveal functional divergence of SP-A1 and SP-
A2: formation of tubular myelin in vivo requires both gene products. J
Biol Chem 2010, 285:11998-12010.
122. Chabot S, Salez L, McCormack FX, Touqui L, Chignard M: Surfactant protein
A inhibits lipopolysaccharide-induced in vivo production of interleukin-
10 by mononuclear phagocytes during lung inflammation. Am J Respir
Cell Mol Biol 2003, 28:347-353.
123. Linke MJ, Ashbaugh AA, Koch JV, Levin L, Tanaka R, Walzer PD: Effects of
surfactant protein-A on the interaction of Pneumocystis murina with its
host at different stages of the infection in mice. J Eukaryot Microbiol 2009,
56:58-65.
124. Morrow DM, Entezari-Zaher T, Romashko J, Azghani AO, Javdan M, Ulloa L,
Miller EJ, Mantell LL: Antioxidants preserve macrophage phagocytosis of
Pseudomonas aeruginosa during hyperoxia. Free Radic Biol Med 2007,
42:1338-1349.
125. Ramadas RA, Wu L, LeVine AM: Surfactant protein A enhances production
of secretory leukoprotease inhibitor and protects it from cleavage by
matrix metalloproteinases. J Immunol 2009, 182:1560-1567.
126. Vazquez de Lara LG, Umstead TM, Davis SE, Phelps DS: Surfactant protein
A increases matrix metalloproteinase-9 production by THP-1 cells. Am J
Physiol Lung Cell Mol Physiol 2003, 285:L899-L906.
127. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M:
Cutting edge: the immunostimulatory activity of the lung surfactant
protein-A involves Toll-like receptor 4. J Immunol 2002, 168:5989-5992.
128. Murakami S, Iwaki D, Mitsuzawa H, Sano H, Takahashi H, Voelker DR,
Akino T, Kuroki Y: Surfactant protein A inhibits peptidoglycan-induced
tumor necrosis factor-alpha secretion in U937 cells and alveolar
macrophages by direct interaction with toll-like receptor 2. J Biol Chem
2002, 277:6830-6837.
Phelps et al. Proteome Science 2011, 9:67
http://www.proteomesci.com/content/9/1/67
Page 20 of 21129. Park J, Choe SS, Choi AH, Kim KH, Yoon MJ, Suganami T, Ogawa Y, Kim JB:
Increase in glucose-6-phosphate dehydrogenase in adipocytes
stimulates oxidative stress and inflammatory signals. Diabetes 2006,
55:2939-2949.
130. LeVine AM, Hartshorn K, Elliott J, Whitsett J, Korfhagen T: Absence of SP-A
modulates innate and adaptive defense responses to pulmonary
influenza infection. Am J Physiol Lung Cell Mol Physiol 2002, 282:L563-L572.
131. Famuyide ME, Hasday JD, Carter HC, Chesko KL, He JR, Viscardi RM:
Surfactant protein-A limits Ureaplasma-mediated lung inflammation in a
murine pneumonia model. Pediatr Res 2009, 66:162-167.
132. Yang S, Milla C, Panoskaltsis-Mortari A, Hawgood S, Blazar BR, Haddad IY:
Surfactant protein A decreases lung injury and mortality after murine
marrow transplantation. Am J Respir Cell Mol Biol 2002, 27:297-305.
133. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S,
Yamamoto M: Transcription factor Nrf2 coordinately regulates a group of
oxidative stress-inducible genes in macrophages. J Biol Chem 2000,
275:16023-16029.
134. Kustermans G, El Mjiyad N, Horion J, Jacobs N, Piette J, Legrand-Poels S:
Actin cytoskeleton differentially modulates NF-kappaB-mediated IL-8
expression in myelomonocytic cells. Biochem Pharmacol 2008,
76:1214-1228.
135. Koptides M, Umstead TM, Floros J, Phelps DS: Surfactant protein A
activates NF-kappa B in the THP-1 monocytic cell line. Am J Physiol 1997,
273:L382-L388.
136. Song M, Phelps DS: Interaction of surfactant protein A with
lipopolysaccharide and regulation of inflammatory cytokines in the THP-
1 monocytic cell line. Infect Immun 2000, 68:6611-6617.
137. Nair S, Doh ST, Chan JY, Kong AN, Cai L: Regulatory potential for
concerted modulation of Nrf2- and Nfkb1-mediated gene expression in
inflammation and carcinogenesis. Br J Cancer 2008, 99:2070-2082.
138. Liu GH, Qu J, Shen X: NF-kappaB/p65 antagonizes Nrf2-ARE pathway by
depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK.
Biochim Biophys Acta 2008, 1783:713-727.
139. Wu MC, Lin X: Prior biological knowledge-based approaches for the
analysis of genome-wide expression profiles using gene sets and
pathways. Stat Methods Med Res 2009, 18:577-593.
140. Goeman JJ, Buhlmann P: Analyzing gene expression data in terms of
gene sets: methodological issues. Bioinformatics 2007, 23:980-987.
141. Floros J, Phelps DS: Pulmonary surfactant protein A; structure, expression,
and its role in innate host defense. In Update of intensive care medicine.
Volume 6. Edited by: Nakos G, Lekka M. Ioannina Greece: University of
Ioannina; 2002:87-102.
142. Haque R, Umstead TM, Ponnuru P, Guo X, Hawgood S, Phelps DS, Floros J:
Role of surfactant protein-A (SP-A) in lung injury in response to acute
ozone exposure of SP-A deficient mice. Toxicol Appl Pharmacol 2007,
220:72-82.
143. Umstead TM, Lu CJ, Freeman WM, Myers JL, Clark JB, Thomas NJ,
Chinchilli VM, Vrana KE, Undar A, Phelps DS: Dual-platform proteomics
study of plasma biomarkers in pediatric patients undergoing
cardiopulmonary bypass. Pediatr Res 2010, 67:641-649.
doi:10.1186/1477-5956-9-67
Cite this article as: Phelps et al.: In vivo rescue of alveolar macrophages
from SP-A knockout mice with exogenous SP-A nearly restores a wild
type intracellular proteome; actin involvement. Proteome Science 2011
9:67.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Phelps et al. Proteome Science 2011, 9:67
http://www.proteomesci.com/content/9/1/67
Page 21 of 21